axgn_Current_Folio

0001558370-17-007934.txt : 20171101 0001558370-17-007934.hdr.sgml : 20171101 20171101165512 ACCESSION NUMBER: 0001558370-17-007934 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171101 DATE AS OF CHANGE: 20171101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AxoGen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 171169649 BUSINESS ADDRESS: STREET 1: 13631 PROGRESS BLVD. STREET 2: SUITE 400 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13631 PROGRESS BLVD. STREET 2: SUITE 400 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 10-Q 1 axgn-20170930x10q.htm 10-Q axgn_Current_Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to______________

Commission file number: 001-36046

AxoGen, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Minnesota		41-1301878
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

13631 Progress Blvd., Suite 400, Alachua, FL		32615
(Address of Principal Executive Offices)		(Zip Code)

386-462-6800

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☒

Non-accelerated filer ☐ (Do not check if a smaller reporting company)		Smaller reporting company ☐

		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

As of October 30, 2017, the registrant had 33,456,091 shares of common stock outstanding.

Table of Contents


Part I - Financial Information
Item 1.	Financial Statements	2

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4.	Controls and Procedures	23


Part II - Other Information

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	26

	Signature Page	28

Forward-Looking Statements

From time to time, in reports filed with the U.S. Securities and Exchange Commission (the “SEC”) (including this Form 10-Q), in press releases, and in other communications to shareholders or the investment community, AxoGen, Inc. (the “Company”, “AxoGen”, “we” or “our”) may provide forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, concerning possible or anticipated future results of operations or business developments. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2017 and 2018 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this Form 10-Q should be evaluated together with the many uncertainties that affect the Company’s business and its market, particularly those discussed in the risk factors and cautionary statements in the Company’s filings with the SEC, including as described in “Risk Factors” included in Item 1A of this Form 10-Q. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Table of Contents

PART 1 — FINANCIAL INFORMATION

ITEM 1 —FINANCIAL STATEMENTS

AxoGen, Inc.

Condensed Consolidated Balance Sheets


	September 30,
	2017		December 31,
	(unaudited)		2016
Assets
Current assets:
Cash and cash equivalents	$	22,041,097	$	30,014,405
Accounts receivable, net of allowance for doubtful accounts of approximately $335,000 and $272,000, respectively		10,200,560		8,052,203
Inventory		6,698,943		5,458,840
Prepaid expenses and other		571,912		511,804
Total current assets		39,512,512		44,037,252
Property and equipment, net		1,763,840		1,494,247
Intangible assets		951,473		828,979
	$	42,227,825	$	46,360,478
Liabilities and Shareholders’ Equity
Current liabilities:
Borrowings under revolving loan agreement	$	4,000,000	$	4,025,023
Accounts payable and accrued expenses		7,072,530		7,002,165
Current maturities of long term obligations		21,596		20,899
Deferred revenue, current		43,576		33,282
Total current liabilities		11,137,702		11,081,369

Long Term Obligations, net of current maturities and deferred financing fees		20,356,698		20,265,745
Deferred lease		105,261		--
Deferred revenue		76,027		92,215
Total liabilities		31,675,688		31,439,329
Shareholders’ equity:
Common stock, $0.01 par value per share; 50,000,000 shares authorized; 33,393,804 and 33,008,865 shares issued and outstanding		333,938		330,088
Additional paid-in capital		136,048,305		132,474,884
Accumulated deficit		(125,830,106)		(117,883,823)
Total shareholders’ equity		10,552,137		14,921,149
	$	42,227,825	$	46,360,478

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)


	Three Months Ended				Nine Months Ended
	September 30,		September 30,		September 30,		September 30,
	2017		2016		2017		2016

Revenues	$	16,046,253	$	11,205,224	$	43,455,390	$	29,698,866
Cost of goods sold		2,504,278		1,697,443		6,697,127		4,637,446
Gross profit		13,541,975		9,507,781		36,758,263		25,061,420
Costs and expenses:
Sales and marketing		9,466,496		7,090,059		27,515,266		20,076,297
Research and development		1,795,292		1,118,358		4,727,551		3,033,521
General and administrative		3,778,612		2,481,051		10,659,756		7,362,063
Total costs and expenses		15,040,400		10,689,468		42,902,573		30,471,881
Loss from operations		(1,498,425)		(1,181,687)		(6,144,310)		(5,410,461)
Other income (expense):
Interest expense		(577,941)		(1,089,134)		(1,639,874)		(3,255,574)
Interest expense — deferred financing costs		(46,110)		(31,748)		(136,711)		(95,254)
Other (expense)		(1,603)		(2,804)		(25,388)		(22,871)
Total other income (expense)		(625,654)		(1,123,686)		(1,801,973)		(3,373,699)
Net Loss	$	(2,124,079)	$	(2,305,373)	$	(7,946,283)	$	(8,784,160)
Weighted Average Common Shares outstanding — basic and diluted		33,286,211		30,152,279		33,146,546		30,075,715
Loss Per Common share — basic and diluted	$	(0.06)	$	(0.08)	$	(0.24)	$	(0.29)

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)


	Nine Months Ended September 30,
	2017		2016
Cash flows from operating activities:
Net loss	$	(7,946,283)	$	(8,784,160)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation		346,839		263,133
Amortization of intangible assets		60,459		48,050
Amortization of deferred financing costs		136,711		95,253
Provision for bad debt		83,733		80,934
Stock-based compensation		2,491,992		1,046,364
Interest added to note payable		—		199,124
Change in assets and liabilities:
Accounts receivable		(2,232,090)		(2,302,701)
Inventory		(1,240,103)		(1,036,859)
Prepaid expenses and other		(60,108)		(260,786)
Accounts payable and accrued expenses		70,365		864,267
Deferred liabilities		99,367		5,727

Net cash used for operating activities		(8,189,118)		(9,781,654)

Cash flows from investing activities:
Purchase of property and equipment		(616,432)		(612,974)
Acquisition of intangible assets		(182,953)		(157,491)

Net cash used for investing activities		(799,385)		(770,465)

Cash flows from financing activities:
Borrowing on revolving loan		41,553,210		—
Payments on revolving loan		(41,578,233)		—
Repayments of long-term debt		(15,589)		—
Debt issuance costs		(29,472)		—
Proceeds from exercise of stock options		1,085,279		645,864

Net cash provided by financing activities		1,015,195		645,864

Net decrease in cash and cash equivalents		(7,973,308)		(9,906,255)
Cash and cash equivalents, beginning of year		30,014,405		25,909,500

Cash and cash equivalents, end of period	$	22,041,097	$	16,003,245

Supplemental disclosures of cash flow activity:
Cash paid for interest	$	1,631,795	$	3,031,528

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Unless the context otherwise requires, all references in these Notes to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. its wholly owned subsidiary AxoGen Corporation (“AC”) and its wholly owned subsidiary AxoGen Europe GmbH, which was established in the fourth quarter of 2016.

1. Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiaries, AxoGen Corporation (“AC”) and AxoGen Europe GmbH, established in the fourth quarter of 2016, as of September 30, 2017 and December 31, 2016 and for the three and nine month periods ended September 30, 2017 and 2016. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“USGAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2016, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2016. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

2. Organization and Business

Business Summary

We are a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

Avance® Nerve Graft and Avive® Soft Tissue Membrane are processed in the United States by AxoGen at its processing facility in Dayton, Ohio. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated and are distributed worldwide exclusively by AxoGen. The AcroVal® Neurosensory and Motor Testing System and AxoTouch® Two Point Discriminator are contract manufactured by Viron Technologies, LLC. (formerly Cybernetics Research Laboratories) (“Viron”) Tucson, Arizona. Viron supplies the AcroVal® and AxoTouch® unpackaged and they are packaged at AxoGen’s distribution facility in Burleson, Texas.

Table of Contents

AxoGen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiary, AC.

3. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The allowance for doubtful accounts reserve balance was approximately $335,000 and $272,000 at September 30, 2017 and December 31, 2016, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.

Inventories

Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, Avive® Soft Tissue Membrane, AcroVal® Neurosensory and Motor Testing System, AxoTouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or market.

We regularly review the inventory status to determine the expected reserve level required. The Company policy is to monitor the shelf life of its products and reserve amounts based on the expiration date of the finished goods inventory. We also reserve a portion of raw materials based on our historical experience of tissue that fails during the inspection and debridement stage due to medical history, serology compliance or poor quality.

Table of Contents

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2014 through 2016; however, there currently are no examinations in process.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

The Company measures all employee stock-based compensation awards using a fair value method and records such expense in its consolidated financial statements. The estimated value of the portion of the award that is ultimately expected to vest, taking into consideration estimated forfeitures based on the Company’s historical forfeiture rate, is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the grant date fair value of stock option awards generally on the date of grant using the Black-Scholes option pricing model.

With respect to performance stock units (“PSUs”), the number of shares that vest and are issued to the recipient is based upon the Company’s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company’s closing stock price on the grant date and its estimate of achieving such performance targets. See further discussion and disclosures in Note 9: “Stock Incentive Plan.”

Use of Estimates

The preparation of consolidated financial statements in conformity with USGAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Earnings (Loss) Per Share of Common Stock

There were no dilutive instruments as of September 30, 2017 and 2016. The basic and diluted weighted average shares outstanding were 33,286,211 and 30,152,279 shares for the three months ended September 30, 2017 and 2016, respectively, and 33,146,546 and 30,075,715 shares for the nine months ended September 30, 2017 and 2016, respectively.

Table of Contents

Basic and diluted net loss per share of common stock for all periods presented is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding and common stock equivalents outstanding, when dilutive. Potentially dilutive common stock equivalents include shares of common stock which would potentially be issued pursuant to stock warrants and stock options. Common stock equivalents are not included in determining the fully diluted loss per share if their effect is antidilutive.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the adoption date. During the quarter ended September 30, 2017, we completed the evaluation of the new standard and a related assessment and review of a representative sample of existing revenue contracts with our customers on our most significant revenue streams. Based upon this assessment, we do not believe there will be a material change to the timing of our revenue recognition. However, during the fourth quarter of 2017 we will continue our preparation for adopting the standard and periodically brief our Audit Committee on our progress. It is likely we will be required to provide additional disclosures in the notes to the consolidated financial statements upon adoption. We have not yet determined the effect of the ASU on our internal control over financial reporting or other changes in business practices and processes but will do so in the design and implementation phase to occur during the remainder of 2017. Additionally, we have not made a decision on which adoption method to utilize. Our evaluation of ASU 2014-09 is ongoing.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230). The ASU was issued intending to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this standard will have a material impact on our consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), guidance that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new guidance is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this guidance will have a material impact on our Statement of Cash Flows.

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting.” ASU 2017-09 provides clarity on which changes to the terms or conditions of share-based payment awards require entities to apply the modification accounting provisions required in Topic 718. ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company does not

Table of Contents

expect that the adoption of ASU 2017-09 will have a material impact on the Company’s results of operations and financial condition.

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

4. Inventories


	September 30,		December 31,
	2017		2016

Finished goods	$	5,157,260	$	4,132,036
Work in process		306,942		205,116
Raw materials		1,234,741		1,121,688
Inventories	$	6,698,943	$	5,458,840

Inventories are net of reserve of approximately $642,000 and $960,000 at September 30, 2017 and December 31, 2016, respectively.

5. Property and Equipment

Property and equipment consist of the following:


	September 30,		December 31,
	2017		2016

Furniture and equipment	$	1,436,733	$	1,270,173
Leasehold improvements		711,319		447,650
Processing equipment		1,763,764		1,577,561
Less: accumulated depreciation and amortization		(2,147,976)		(1,801,137)
Property and equipment, net	$	1,763,840	$	1,494,247

6. Intangible Assets

The Company’s intangible assets consist of the following:


	September 30,		December 31,
	2017		2016

License agreements	$	1,003,512	$	984,342
Patents		461,712		308,212
Less: accumulated amortization		(513,751)		(463,575)
Intangible assets, net	$	951,473	$	828,979

Table of Contents

approximately $60,000 and $48,000 for the nine months ended September 30, 2017 and 2016, respectively. As of September 30, 2017, future amortization of license agreements and patents (i) for the remainder of fiscal year 2017 is $19,000, (ii) for the fiscal years 2018 through 2022 is expected to be $74,000 per year, and (iii) after 2022 an aggregate $563,000.

License Agreements

The Company has entered into multiple license agreements (together, the “License Agreements”) with the University of Florida Research Foundation and the University of Texas at Austin. Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies;

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

Currently, under the University of Texas at Austin’s agreement, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. A milestone fee to the University of Florida Research Foundation of $2,000 is due if AxoGen receives FDA approval of its Avance® Nerve Graft, a milestone fee of $25,000 is due upon the first commercial use of certain licensed technology to provide services to manufacture products for third parties and a milestone fee of $10,000 is due upon the first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.

Royalty fees were approximately $319,000 and $214,000 during the three months ended September 30, 2017 and 2016, respectively, and approximately $860,000 and $583,000 during the nine months ended September 30, 2017 and 2016, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

Table of Contents

7. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:


	September 30,		December 31,
	2017		2016

Accounts payable	$	2,104,119	$	3,614,015
Accrued expenses		1,361,769		804,691
Accrued compensation		3,606,642		2,583,459
Accounts Payable and Accrued Expenses	$	7,072,530	$	7,002,165

8. Term Loan Agreements and Long-Term Debt

Term Loan Agreement and Long Term Debt consist of the following:


	September 30,		December 31,
	2017		2016

Term Loan Agreement with MidCap Financial Trust (“MidCap”) for a total of $21,000,000, net of $663,946 of unamortized deferred financing fees at September 30, 2017, and $771,185 at December 31, 2016. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 8.5% rate.	$	20,336,054	$	20,228,815

Revolving Loan Agreement with MidCap for up to $10,000,000 with borrowings based upon eligible accounts receivable and inventory. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 5.0% rate.		4,000,000		4,025,023

Equipment Lease Agreement with Cisco Capital for a total lease amount of $58,875 which has a 36 month term and requires no lease payments for the first three months of the lease and 33 equal payments of principal and interest until the end of the term. Interest on the lease is payable monthly at 3.5% per annum.		42,240		57,829
Total		24,378,294		24,311,667
Less current revolving loan		(4,000,000)		(4,025,023)
Less current maturities of long term debt		(21,596)		(20,899)
Long-term portion	$	20,356,698	$	20,265,745

Credit Facilities

Three Peaks Term Loan Agreement and Revenue Interest Agreement

On November 12, 2014, AxoGen, as borrower, and AC, as guarantor, entered into that certain Term Loan Agreement (the “Three Peaks Term Loan Agreement”), dated November 12, 2014, by and among AxoGen, as borrower, AC, as guarantor, the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP, as administrative and collateral agent for the lenders. Under the Three Peaks Term Loan Agreement, Three Peaks provided AxoGen a term loan of $25 million which had a six-year term and required interest only payments and a final principal payment due at the end of the term. Interest was payable quarterly at 9.0% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 resulted in a 10% rate.

Table of Contents

In addition, on November 12, 2014, AxoGen entered into that certain Revenue Interest Agreement (the “Revenue Interest Agreement”) with Three Peaks. Royalty payments were based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12-month period.

On October 26, 2016, the Three Peaks Term Loan Agreement and Revenue Interest Agreement were paid in full and the Company had no further obligations pursuant to such agreements.

MidCap Term Loan Agreement

On October 25, 2016 (the “Closing Date”), AxoGen and AC, each as borrowers, entered into a Credit and Security Agreement (Term Loan) (the ''MC Term Loan Agreement") with the lenders party thereto and MidCap Financial Trust (“MidCap”), as administrative agent and a lender. Under the MC Term Loan Agreement, MidCap provided the Company a term loan in the aggregate principal amount of $21 million (the "Term Loan") which has a maturity date of May 1, 2021 and requires interest only payments through December 1, 2018, and thereafter, 30 monthly payments of principal and interest resulting in the Term Loan being fully paid by the maturity date. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5%. In addition to the interest charged on the Term Loan, the Company is also obligated to pay certain fees, including an annual agency fee of 0.25% of the aggregate principal amount of the Term Loan.

The Company has the option at any time to prepay the Term Loan in whole or in part, subject to certain conditions, a prepayment fee, and a 5.0% exit fee as specified in the MC Term Loan Agreement. The prepayment fee is determined by multiplying the amount being prepaid by the following applicable percentage amount: (a) 3.0% during the first year following the Closing Date; (b) 2.0% during the second year following the Closing Date, and (c) 1.0% thereafter. However, no prepayment fee is due in the event the prepayment is a result of refinancing the Term Loan and Revolving Loan with MidCap or an affiliate of MidCap.

MidCap Revolving Loan Agreement

In addition, on October 25, 2016, AxoGen and AC, each as borrowers, also entered into a Credit and Security Agreement (Revolving Loan) (the ''Revolving Loan Agreement") with the lenders party thereto and MidCap, as administrative agent and a lender. Under the Revolving Loan Agreement, MidCap agreed to lend to the Company up to $10 million under a revolving credit facility (the "Revolving Loan") which amount may be drawn down by the Company based upon an available borrowing base which includes certain accounts receivable and inventory. The Revolving Loan may be increased to up to $15 million at the Company’s request and with the approval of MidCap. The maturity date of the Revolving Loan is May 1, 2021. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% on outstanding advances. In addition to the interest charged on the Revolving Loan, the Company is also obligated to pay certain fees, including a collateral management fee of 0.5% per annum of the principal amount outstanding on the Revolving Loan from time to time and an unused line fee of 0.5% per annum on the difference between the average amount outstanding on the Revolving Loan minus the total amount of the Revolving Loan commitment. The Revolving Loan is subject to a minimum balance, such that the Company pays the greater of: (i) interest accrued on the actual amount drawn under the Revolving Loan Facility; and (ii) interest accrued on 30% of the average borrowing base. If the Revolving Loan is terminated or permanently reduced prior to the maturity date, MidCap is owed a deferred revolving loan origination fee as specified in the Revolving Loan Agreement. No deferred revolving loan origination fee is due in the event the Revolving Loan is paid in full or the termination of the revolving credit facility is a result of refinancing the Term Loan and Revolving Loan with MidCap or an affiliate of MidCap.

The MC Term Loan Agreement and the Revolving Loan Agreement each contain covenants that place restrictions on AxoGen’s operations, including, without limitation, covenants related to debt restrictions, investment restrictions, dividend restrictions, restrictions on transactions with affiliates and certain revenue covenants. MidCap, on behalf of the lenders under the agreements, has a first perfected security interest in the assets of the Company to guarantee the payment in full of the agreements. Upon the payment in full to MidCap and the lenders of the Term Loan Agreement and Revolving Loan Agreement, the Company would have no further obligations to MidCap or the lenders under the Term Loan Agreement or the Revolving Loan Agreement. As of September 30, 2017, we were in compliance with the loan covenants.

Table of Contents

The Company used the aggregate proceeds of $25 million from the Term Loan and the Revolving Loan to pay the outstanding indebtedness owed to Three Peaks and the other lenders to terminate the Three Peaks Term Loan Agreement and the Revenue Interest Agreement. Expenses and fees of approximately $800,000 to complete the negotiation and documentation of the Term Loan and the Revolving Loan and prepayment fees of approximately $2.3 million owed to Three Peaks were paid from the Company’s own funds.

Interest expense for the year ended December 31, 2016 was approximately $5,386,000 compared to $3,989,000 for the year ended December 31, 2015. The 2016 amount includes a final payment to Three Peaks of approximately $2,447,000 inclusive of prepayment fees and accrued interest through October 25, 2016. In addition, as a result of the accounting treatment for the Three Peaks transaction, the Company had previously recorded a total of $747,000 of deferred interest charges which were offset against these prepayment fees. The net impact of these transactions resulted in a net interest charge of approximately $1,700,000 in the year which was included in interest expense for the year ended December 31, 2016. Additionally, as the result of the extinguishment of the debt facility with Three Peaks, the Company wrote off approximately $750,000 of prepaid financing fees to interest expense – deferred financing costs in 2016.

As of September 30, 2017, the Term Loan had an outstanding balance of $21.0 million, with an interest rate of 8.5%. Also, at September 30, 2017, the borrowing base under the Revolving Loan Agreement was approximately $6,879,000 and the Company had an outstanding balance on the Revolving Loan facility of $4,000,000 with an interest rate of 5.0%.

Annual maturities of the Company’s long-term obligations are as follows:


Year Ending December 31	Amount
2017	$	5,310
2018		1,421,834
2019		8,415,096
2020		8,400,000
2021		2,800,000
		21,042,240
Less unamortized debt issuance costs		(663,946)
TOTAL	$	20,378,294

9. Stock Incentive Plan

The Company maintains the AxoGen 2010 Stock Incentive Plan, as amended and restated (the “AxoGen Plan”), which allows for issuance of incentive stock options, non-qualified stock options, performance stock units (PSU) and restricted stock awards (RSU) to employees, directors and consultants at exercise prices not less than the fair market value at the date of grant. At the 2016 Annual Meeting of Shareholders, the AxoGen Plan was amended to increase the number of shares of common stock authorized for issuance under the AxoGen Plan to 5,500,000 shares. Additionally, at the 2017 Annual Meeting of Shareholders held on May 24, 2017, the AxoGen Plan was amended to increase the number of shares of common stock authorized for issuance under the AxoGen Plan to 7,700,000 shares. At the 2017 Annual Meeting of Shareholders, the shareholders approved the adoption of the AxoGen 2017 Employee Stock Purchase Plan (the “2017 ESPP”), which allows for eligible employees to acquire shares of our common stock through payroll deductions at a discount from market value. The 2017 ESPP authorized a total of 600,000 shares of our common stock with the first offering period expected to begin January 1, 2018.

The options granted to employees typically vest 25% one year after the grant date and 12.5% every six months thereafter for the remaining three-year period until fully vested after four years and those to directors and certain executive officers have vested 25% per quarter over one year or had no vesting period. Options issued to consultants have vesting provisions based on the engagement ranging from no vesting to vesting over the service period ranging from three to four years. Options typically have terms ranging from seven to ten years.

Table of Contents

The Company recognized stock-based compensation expense of $919,026 and $293,575 for the three months ended September 30, 2017 and 2016, respectively, and $2,491,992 and $1,046,364 for the nine months ended September 30, 2017 and 2016, respectively, which consisted of compensation expense related to employee stock options, PSUs and RSUs based on the value of share-based payment awards that are ultimately expected to vest during the period.

The Company estimates the fair value of each option award issued under such plans on the date of grant using the Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the Company’s merger with LecTec Corporation in 2011 (the “Merger”), and based on the Company’s common stock for periods subsequent to the Merger. However, for options granted on and after December 29, 2016 the Company began using a Multiple Point Black-Scholes option-pricing model which uses a weighted average of historical volatility and peer company volatility. The Company determines the expected life giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award.

The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:


Nine months ended September 30,	2017		2016

Expected term (in years)	6.16		4.00
Expected volatility	50.72	%	61.71	%
Risk free rate	2.07	%	1.22	%
Expected dividends	—	%	—	%

The Company granted stock options to purchase 635,525 shares of its common stock pursuant to the AxoGen Plan, for the nine months ended September 30, 2017. The weighted average fair value of options granted at market during the nine months ended September 30, 2017 and 2016 was $6.77 and $3.00 per option, respectively

At September 30, 2017, the total future stock compensation expense related to non-vested awards is expected to be approximately $9,086,000.

10. Public Offering of Common Stock

On October 7, 2016, AxoGen entered into an underwriting agreement with JMP Securities LLC, as representative of the several underwriters (collectively, the “Underwriters”), to issue and sell 2,333,334 shares of the Company’s common stock in an underwritten registered public offering (the “2016 Offering”) at an offering price of $7.50 per share. Pursuant to the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 350,000 shares of common stock, which the underwriters exercised in full on October 7, 2016. Five of the Company’s directors and officers purchased an aggregate of approximately 32,666 shares of common stock in the 2016 Offering and such purchases were made on the same terms and conditions as purchases by the public in the 2016 Offering. The 2016 Offering closed on October 13, 2016, and the Company received net proceeds of approximately $18.67 million from the sale of 2,683,334 shares of common stock, which includes the additional 350,000 shares of common stock, after deducting the underwriting discounts and commissions and estimated offering expenses.

11. Commitments and Contingencies

Operating Leases

Table of Contents

that the Expiration Date (as defined in the Fourth Amendment) of the Existing SNH Lease will be extended to approximately five years from the Occupancy Date (as defined in the Fourth Amendment) which was June 2016. The original expiration date of the Current Premises remains unchanged; provided, however, that AC shall have the right to extend the Current Premises Term (as defined in the Fourth Amendment) for three additional periods (the “Current Premises Extended Term”), the first such Current Premises Extended Term to commence on November 1, 2018 and end on October 31, 2019, the second such Current Premises Extended Term to commence on November 1, 2019 and end on October 31, 2020, and the third such Current Premises Extended Term to commence on November 1, 2020 and end on the Expiration Date. AC also has the right to extend the term of the then current Leased Premises (as defined in the Fourth Amendment) for an additional period of five years commencing on the day immediately after the Expiration Date. AxoGen’s annual cost of such property ranges from approximately $248,000 to $332,000 per year.

On October 25, 2013, AC entered into a commercial lease with Ja-Cole L.P. (“Ja-Cole”). Under the terms of the commercial lease, AxoGen occupied 5,400 square feet of warehouse/office space in its Burleson, Texas Distribution Facility until November 30, 2016 at an annual cost of $43,200. On April 21, 2015, AxoGen entered into a new commercial lease, as amended by the addendum on such date (as amended, the “Ja-Cole Lease”), with Ja-Cole. The new commercial lease superseded and replaced the original lease with Ja-Cole dated October 25, 2013. Under the terms of the Ja-Cole Lease, AxoGen leased an additional 2,100 square feet of warehouse space at the Distribution Facility. The Ja-Cole Lease is for a three-year term expiring April 21, 2018. On October 25, 2016, AC entered into Commercial Lease Amendment 2 (the “Ja-Cole Amendment”) to the Ja-Cole Lease. Under the terms of the Ja-Cole Amendment, AxoGen leased an additional 2,500 square feet of warehouse/office space at the Distribution Facility. The Distribution Facility now comprises a total of 10,000 square feet, all of which, pursuant to the Ja-Cole Amendment, will be leased until March 31, 2019. The annual rental cost of the entire Distribution Facility is now approximately $88,000. The Burleson facility houses raw material storage and product distribution while allowing same day fulfillment of orders for both coasts of the United States.

On January 23, 2017, AC entered into a lease (the “New SNH Lease”) for a five year term commencing April 1, 2017 with SNH Medical Office Properties Trust, a Maryland real estate investment trust (“SNH”), for 1,431 square feet at 13709 Progress Boulevard, Alachua, Florida 32615. Pursuant to the New SNH Lease, AC is to use the space for general office and biomedical research uses. SNH is the landlord of AC’s currently leased corporate headquarters facility at 13631 Progress Boulevard, Alachua, Florida 32615. AC’s additional annual cost of the Premises range from approximately $25,800 to $29,000 over the life of the lease.

In addition, AxoGen leases space and maintains records at certain other facilities, including the Company’s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.

Estimated future minimum rental payments on the leases are as follows:


Year Ending December 31	Amount
2017 (9 months ended)	$	98,835
2018		437,900
2019		182,250
2020		165,116
2021		86,638
TOTAL	$	970,739

Total rent expense for the Company’s leased office and lab space for the nine months ended September 30, 2017 and 2016 was approximately $368,000 and $340,000, respectively.

Service Agreements

Table of Contents

with Community Blood Center (d/b/a Community Tissue Services) (“CTS”), Dayton, Ohio, an FDA registered tissue establishment. Processing of the Avance® Nerve Graft pursuant to the CTS agreement began in February 2016. The CTS agreement is for a five-year term, subject to earlier termination by either party for cause, or after August 6, 2017 without cause, upon 18 months’ notice. Under the CTS agreement, AxoGen pays CTS a facility fee for clean room/manufacturing, storage and office space. CTS also provides services in support of AxoGen’s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.

In August 2008, the Company entered into an agreement to distribute the AxoGuard® products worldwide in the field of peripheral nerve repair, and the parties subsequently amended the agreement in March, 2012. The agreement expires in August 2022. The Cook Biotech agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the AxoGuard® products. Under the agreement, AxoGen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders.

In December 2011, the Company also entered into a Master Services Agreement for Clinical Research and Related Services. The Company was required to pay $151,318 upon execution of this agreement and the remainder monthly based on activities associated with the execution of AxoGen’s phase 3 pivotal clinical trial to support a biologics license application (BLA) for Avance® Nerve Graft.

Certain executive officers of the Company are parties to employment contracts. Such contracts have severance payments for certain conditions including change of control.

12. Retirement Plan

AxoGen 401(k) Plan

The Company adopted the AxoGen 401(k) plan (the “401(k) Plan”) in December 2015 with contributions starting in January 2016. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee’s annual salary and 1% of the next 2% of the employee’s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately. The Company contributed approximately $334,000 in matching funds during 2016. Employer contributions to the 401(k) Plan for the three months ending September 30, 2017 and 2016 were approximately $114,000 and $76,000, respectively, and for the nine months ending September 30, 2017 and 2016 were approximately $320,000 and $247,000, respectively.

Table of Contents

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context otherwise requires, all references in this report to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. its wholly owned subsidiary AxoGen Corporation (“AC”) and its wholly owned subsidiary AxoGen Europe GmbH, which was established in the fourth quarter of 2016.

OVERVIEW

AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal™ Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

Revenue from the distribution of AxoGen’s nerve repair products, the Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector and Avive® Soft Tissue Membrane, in the United States is the main contributor to AxoGen’s total reported sales and has been the key component of our growth to date. We estimate that there are approximately 5,100 accounts (e.g., hospitals, specialty surgery centers) performing nerve repair across the United States.

We have experienced that surgeons initially are cautious adopters for nerve repair products. Surgeons typically start with a few cases and then wait and review the results of these initial cases which can take from six to twelve months, or longer. Active accounts are usually past their initial wait period and have developed some level of product reorder. These active accounts have typically gone through their buying committee approval process, have at least one surgeon who has converted a portion of his or her treatment algorithms of nerve repair so as to use at least one of AxoGen’s products and have ordered such product(s) at least six times within the last twelve months prior to the review date. The number of active accounts at the end of the third quarter of 2017 were approximately 563, representing an increase of 36% compared to the third quarter of 2016.

As such, revenue growth is primarily due to increased purchases from active accounts, followed by revenue growth from new accounts. Each new period of measurement is thus benefited from growth in active accounts which may include those that were new accounts in the prior measurement period. We have continued to broaden our sales and marketing focus which we expect to have a continuing positive contribution to our revenue growth in the long term.

Table of Contents

Results of Operations

Comparison of the Three Months Ended September 30, 2017 and 2016

Revenues

Revenues for the three months ended September 30, 2017 increased 42.9% to $16.0 million as compared to $11.2 million for the three months ended September 30, 2016. We continued to experience growth in the number of active accounts, as well as product portfolio penetration in those accounts and, to a lesser extent, the establishment of new accounts, which drove our revenue growth in terms of units.

Gross Profit

Gross profit for the three months ended September 30, 2017 increased 42.1% to $13.5 million as compared to $9.5 million for the three months ended September 30, 2016. This increase is primarily attributable to the increased revenues. Gross margin decreased slightly to 84.4% for the three months ended September 30, 2017 as compared to 84.9% for the same period in 2016 primarily due to manufacturing yield variances and product mix.

Costs and Expenses

Total costs and expenses increased 40.2% to $15.0 million for the three months ended September 30, 2017 as compared to $10.7 million for the three months ended September 30, 2016, primarily due to increased sales activity, costs associated with increases in personnel to support our growth (including non-cash stock compensation), increases in research and development, which includes our RECON clinical trial, and increased general expenses associated with our continuing growth. As a percentage of total revenue, total cost and expenses decreased to 93.8% for the three months ended September 30, 2017 as compared to 95.5% for the comparable three months ended September 30, 2016, primarily as a result of the total revenue increase outpacing the increase in total costs in expenses.

Sales and marketing expenses increased 33.8% to $9.5 million for the three months ended September 30, 2017 as compared to $7.1 million for the three months ended September 30, 2016. This increase was primarily due to increased compensation expenses related to our direct sales force as a result of continued increased sales and hiring of additional personnel, increased commissions to independent distributors as a result of increased sales, and increased marketing research activity to drive market penetration. As a percentage of total revenue, sales and marketing expenses were 59.4% for the three months ended September 30, 2017 as compared to 63.4% for the three months ended September 30, 2016, primarily as a result of the total revenue increase continuing to outpace the increase in sales and marketing expenses.

General and administrative expenses increased 52.0% to $3.8 million for the three months ended September 30, 2017 as compared to $2.5 million for the three months ended September 30, 2016, primarily as the result of increased compensation (including non-cash stock compensation) and recruiting fees, and increased general expenses related to our growth. As a percentage of total revenues, general and administrative expenses were 23.8% for the three months ended September 30, 2017 as compared to 22.3% for the three months ended September 30, 2016, primarily as a result of the increase in general and administrative expenses outpacing the increase in total revenue.

Research and development expenses increased 63.6% to $1.8 million for the three months ended September 30, 2017 as compared to $1.1 million for the three months ended September 30, 2016. Research and development costs include our product development and clinical efforts substantially focused on our biologics license application (BLA) for the Avance® Nerve Graft as well as efforts in support of the RANGER Registry, investigator initiated studies and development of new products and product applications. This activity varies from quarter to quarter due to the timing of certain projects. The increase in expenses for the third quarter of 2017 relates to expenditures for such clinical activity and increased compensation and recruiting fees. Although our products are developed for sale in their current use, we continue to conduct development efforts focused on new products and new product applications. We are active in pursuing research grants to support research and early product development. As a percentage of total revenue, research and development expenses for the three months ended September 30, 2017 were 11.2% as compared to 10.0% for the three months ended September 30, 2016, as we continued to invest in our product development pipeline and clinical studies.

Table of Contents

Other Income and Expenses

Interest expense decreased 47.5% to $578,000 for the three months ended September 30, 2017 as compared to $1.1 million for the three months ended September 30, 2016, due to the lower interest rate as a result of the refinancing of our debt facility in October 2016.

Interest expense – deferred financing costs increased 43.8% to $46,000 for the three months ended September 30, 2017 as compared to $32,000 for the three months ended September 30, 2016, due to the deferred financing costs associated with the new debt facility being amortized over a shorter term than our previous debt facility.

Income Taxes

We had no income tax expenses or income tax benefit for each of the three months ended September 30, 2017 and 2016 due to the incurrence of net operating losses in each of these periods.

Comparison of the Nine Months Ended September 30, 2017 and 2016:

Revenues

Revenues for the nine months ended September 30, 2017 increased 46.5% to $43.5 million as compared to $29.7 million for the nine months ended September 30, 2016. This increase was primarily the result of continued unit revenue growth in active accounts and, to a lesser extent, the establishment of new accounts, as well as the product price increase we implemented in March 2017 across all of our product lines.

Gross Profit

Gross profit for the nine months ended September 30, 2017 increased 46.6% to $36.8 million as compared to $25.1 million for the nine months ended September 30, 2016. This increase was primarily attributable to the increased revenues. Gross margin improved slightly to 84.6% for the nine months ended September 30, 2017 as compared to 84.5% for the same period in 2016.

Costs and Expenses

Total cost and expenses increased 40.7% to $42.9 million for the nine months ended September 30, 2017 as compared to $30.5 million for the nine months ended September 30, 2016. These increases were due primarily to increased sales activity, costs associated with increases in compensation (including non-cash stock compensation), increases in research and development, which includes our RECON clinical trial, and increased general expenses associated with our continuing growth. As a percentage of total revenue, total costs and expenses decreased to 98.6% for the nine months ended September 30, 2017 as compared to 102.7% for the nine months ended September 30, 2016, primarily as a result of the total revenue increase outpacing the increase in total costs in expenses.

Sales and marketing expenses increased 36.8% to $27.5 million for the nine months ended September 30, 2017 as compared to $20.1 million for the nine months ended September 30, 2016, primarily due to increased compensation expenses related to our direct sales force as a result of increased sales and hiring of additional personnel, increased commissions to independent distributors as a result of increased sales, the expansion of our surgeon education program, and increased marketing activity. As a percentage of total revenue, sales and marketing expenses were 63.2% for the nine months ended September 30, 2017 as compared to 67.7% for the nine months ended September 30, 2016, primarily as a result of the total revenue increase continuing to outpace the increase in sales and marketing expenses.

General and administrative expenses increased 44.6% to $10.7 million for the nine months ended September 30, 2017 as compared to $7.4 million for the nine months ended September 30, 2016. The increase was primarily the result of increased compensation (including non-cash stock compensation) and recruiting, professional fees and increased general expenses related to our growth. As a percentage of total revenue, general and administrative expenses decreased slightly to 24.6% for the nine months ended September 30, 2017 as compared to 24.9% for the nine months ended September 30, 2016, primarily as a result of the increase in total revenue outpacing the increase in general and administrative expenses.

Table of Contents

Research and development costs increased 56.7% to $4.7 million in the nine months ended September 30, 2017 as compared to $3.0 million for the nine months ended September 30, 2016. Research and development costs include our product development and clinical efforts substantially focused on our BLA for the Avance® Nerve Graft as well as efforts in support of the RANGER Registry, investigator initiated studies and development of new products and product applications. This activity varies from period to period due to the timing of certain projects. The increase in expenses for the first nine months of 2017 relates to expenditures for such clinical activity, including increased personnel to support both clinical and product development activity, offset by certain projects that have been completed. Although our products are developed for sale in their current use, we continue to conduct development efforts focused on new products and new product applications. We are active in pursuing research grants to support research and early product development. As a percentage of revenues, research and development expenses for the nine months ended September 30, 2017 were 10.8% as compared to 10.1% for the nine months ended September 30, 2016, as we continued to invest in our product development pipeline and clinical studies.

Other Income and Expenses

Interest expense decreased 51.5% to $1.6 million for the nine months ended September 30, 2017 as compared to $3.3 million for the nine months ended September 30, 2016. This decrease was due to the lower interest rate as a result of the refinancing of our debt facility in October 2016.

Interest expense – deferred financing costs increased 44.2% to $137,000 for the nine months ended September 30, 2017 as compared to $95,000 for the nine months ended September 30, 2016, due to the deferred financing costs associated with the new debt facility being amortized over a shorter term than our previous debt facility.

Income Taxes

We had no income tax expenses or income tax benefit for each of the nine months ended September 30, 2017 and 2016 due to the incurrence of net operating loss in both of these periods.

Effect of Inflation

Inflation has not had a significant impact on the Company’s operations or cash flow during 2017 or the fiscal years ended 2016, 2015 and 2014.

Liquidity and Capital Resources

Cash Flow Information

As of September 30, 2017, the Company had cash and cash equivalents of $22.0 million, a decrease of $8.0 million from $30.0 million at December 31, 2016. Cash disbursements in the first nine months included a $1.2 million payment of the 2016 all-employee performance bonus accrual.

The Company had working capital of $28.4 million and a current ratio of 3.55 at September 30, 2017, compared to working capital of $33.0 million and a current ratio of 3.97 at December 31, 2016. The decrease in working capital and the current ratio at September 30, 2017 as compared to December 31, 2016 was due primarily to the use of working capital to fund operations including the increase in inventory and accounts receivable. The Company believes it has sufficient cash resources to meet its liquidity requirements for at least the next 12 months based on its expected level of operations.

AxoGen’s future capital requirements depend on a number of factors, including, without limitation, continued adoption of its products by surgeons and growth of its revenues, continued expansion and development of its direct sales force, expenses associated with its surgeon education programs, maintaining its gross margins, expenses related to its facilities for production and distribution of products and general market conditions. AxoGen could face increasing capital needs depending on the extent to which AxoGen is unable to increase revenues.

If AxoGen needs additional capital in the future, it may raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional equity would result in dilution to AxoGen’s shareholders.

Table of Contents

There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt. Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain actions, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.

The Company’s principal sources and uses of funds are explained below:

Cash used in operating activities

Operating activities for the nine months ended September 30, 2017 used $8.2 million of cash as compared to using $9.8 million of cash for operating activities for the nine months ended September 30, 2016. This decrease in cash used for operating activities of approximately $1.6 million is primarily attributable to lower net losses after adjusting for higher non-cash expenses, including stock-based compensation and depreciation in 2017 compared to 2016.

Cash used for investing activities

Investing activities for the nine months ended September 30, 2017 used $799,000 of cash as compared to using $770,000 of cash for the nine months ended September 30, 2016. This increase in cash used for investing activities of $29,000 is principally attributable to ongoing investments for capital equipment and intellectual property for the growth of our business.

Cash provided by financing activities

Financing activities for the nine months ended September 30, 2017 provided $1.0 million of cash as compared to providing $646,000 of cash for the nine months ended September 30, 2016. These amounts were primarily attributable to proceeds from the exercise of stock options.

Credit Facilities

On November 12, 2014, AxoGen, as borrower, and AC, as guarantor, entered into that certain Term Loan Agreement (the “Three Peaks Term Loan Agreement”), with Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP, as administrative and collateral agent for the lenders. Under the Three Peaks Term Loan Agreement, Three Peaks provided AxoGen a term loan of $25 million which had a six-year term and required interest only payments and a final principal payment due at the end of the term. Interest was payable quarterly at 9.0% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 resulted in a 10% rate. AxoGen had to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks had a first perfected security interest in the assets of AxoGen.

On October 26, 2016, the Three Peaks Term Loan Agreement and Revenue Interest Agreement were paid in full and the Company had no further obligations pursuant to such agreements.

On October 25, 2016, AxoGen and AC, each as borrowers, entered into a Credit and Security Agreement (the ''MC Term Loan Agreement") with the lenders party thereto and MidCap Financial Trust (“MidCap”), as administrative agent and a lender. Under the MC Term Loan Agreement, MidCap provided the Company a term loan in the aggregate principal amount of $21 million (the "Term Loan") which has a maturity date of May 1, 2021 and requires interest only payments through December 1, 2018, and thereafter, 30 monthly payments of principal and interest resulting in the Term Loan being fully paid by the maturity date. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5%. Additionally, AxoGen and AC, each as borrowers, also entered into a Credit and Security Agreement (the ''Revolving Loan Agreement") with the lenders party thereto and MidCap, as administrative agent and a lender. Under the Revolving Loan Agreement, MidCap agreed to lend to the Company up to $10 million under a revolving credit facility (the "Revolving Loan") which amount may be drawn down by the Company based upon an available borrowing base which includes certain accounts receivable and inventory. The Revolving Loan may be increased to up to $15 million at

Table of Contents

the Company’s request and with the approval of MidCap. The maturity date of the Revolving Loan is May 1, 2021. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% on outstanding advances.

Under the MidCap Term Loan Agreement and the Revolving Loan Agreement, the Company must maintain certain covenants including, but not limited to, limiting new indebtedness, restrictions on the payment of dividends and maintaining certain levels of revenue. MidCap, on behalf of the lenders under the Revolving Loan Agreement, has a first perfected security interest in the assets of the Company to guarantee the payment in full of the MC Term Loan and Revolving Loan. Upon the payment in full to MidCap and the lenders of the MC Term Loan and Revolving Loan, the Company would have no further obligations to MidCap or the lenders under the MC Term Loan or the Revolving Loan or the Revolving Loan Agreement.

As of September 30, 2017, the Term Loan facility had an outstanding balance of $21.0 million, with an interest rate of 8.5%. Also, at September 30, 2017, the Borrowing Base (as defined in the Revolving Loan Agreement) under the Revolving Loan Agreement was approximately $6.9 million and the Company had an outstanding balance on the Revolving Loan facility of $4.0 million with an interest rate of 5.0%.

Public Offering of Common Stock

On October 7, 2016, AxoGen entered into an underwriting agreement (the “Underwriting Agreement”) with JMP Securities LLC, as representative of the several underwriters (collectively, the “Underwriters”), to issue and sell 2,333,334 shares of the Company’s common stock in an underwritten registered public offering (the “2016 Offering”) at an offering price of $7.50 per share. Pursuant to the Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 350,000 shares of common stock, which the underwriters exercised in full on October 7, 2016. Five of the Company’s directors and officers purchased an aggregate of approximately 32,666 shares of common stock in the 2016 Offering and such purchases were made on the same terms and conditions as purchases by the public in the 2016 Offering. The 2016 Offering closed on October 13, 2016, and the Company received net proceeds of approximately $18.67 million from the sale of 2,683,334 shares of common stock, which includes the additional 350,000 shares of common stock, after deducting the underwriting discounts and commissions and estimated offering expenses. The Company intends to use, and has been using, the net proceeds from the 2016 Offering for general working capital purposes and expanded development of nerve repair markets. However, the Company’s management retains broad discretion over the allocation of the net proceeds.

Material Commitments

At September 30, 2017, the Company had entered into an agreement with a local commercial general contractor for the expansion of its headquarters facility in Alachua, Florida to remodel and finish additional leased space adjacent to its current facility for $285,000, which it expects to complete by December 31, 2017.

Off-Balance Sheet Arrangements

AxoGen does not have any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The following discussion about our exposure to market risk of financial instruments contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described due to a number of factors, including uncertainties associated with general economic conditions and conditions impacting our industry.

Table of Contents

We are exposed to certain market risks in the ordinary course of business.

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivables. We maintain our accounts for cash and cash equivalents principally at one major bank and one investment firm in the United States. We have not experienced any losses on our deposits of our cash and cash equivalents.

With respect to accounts receivable, we perform credit evaluations of our customers and do not require collateral. There have been no material losses on accounts receivables. Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.

We are subject to market risk from exposure to changes in interest rates based upon our financing, investing and cash management activities. Changes in interest rates affect interest income earned on cash and cash equivalents and interest expense on long term and revolving credit arrangements. We have not entered into derivative transactions related to cash and cash equivalents or debt. Our borrowings under our term loan and credit facilities expose us to market risk related to changes in interest rates. As of September 30, 2017, our long term debt was approximately $21.0 million with an interest rate of 8.0% per annum plus the greater of LIBOR or 0.5% and our revolving loan was $4.0 million with an interest rate of 4.5% per annum plus the greater of LIBOR or 0.5% We do not expect changes in interest rates to have a material adverse effect on our income or our cash flows in 2017. However, we can give no assurance that interest rates will not significantly change in the future.

The value of the U.S. dollar compared to the Euro has little to no effect on our financial results. International business transactions are currently invoiced in U.S. dollars. As a result, the Company has minimal exposure related to exchange rate fluctuations.

In the United States, we sell our products directly to hospitals and clinics in the local currency. Revenue is recognized as disclosed in Note 3 - Summary of Significant Accounting Policies - Revenue Recognition in our Notes to Condensed Consolidated Financial Statements.

In all international markets, we sell our products to independent distributors who, in turn, sell to medical clinics. These sales of our products in these countries through independent distributors are denominated in United States dollars.

We do not believe our operations are currently subject to significant market risks for foreign currency exchange rates, commodity prices or other relevant market price risks of a material nature.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Table of Contents

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2017 and concluded that our disclosure controls and procedures were still not effective as of such date due to the same material weaknesses in internal control over financial reporting described in Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”).

Changes in Internal Controls Over Financial Reporting

During the three months ended September 30, 2017, the Company made the following changes to the design of its internal controls over financial reporting:

Improved procedures to test, evaluate and document the assumptions utilized in significant estimates; and

Enhanced the scope and procedures of the testing and documentation of quarterly cycle counts of consignment inventory.

We believe these changes in internal controls over financial reporting address the material weaknesses relating to the design and operation of key controls around the use of judgment and calculations of significant estimates, as well as quarterly cycle count procedures related to consigned inventories, described in our 2016 Annual Report. Although these changes have been made, the material weaknesses or deficiencies will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. Weaknesses or deficiencies in our internal control over financial reporting may be identified when we assess the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017, or during the audit by our independent registered public accounting firm of the Company’s internal control over financial reporting as of December 31, 2017.

Other than such changes, there were no other changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II –OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

From time to time, we may be a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business, some of which relate to some or all of certain of our patents. While it is not possible to determine the outcome of these matters, management does not expect that the ultimate costs to resolve these matters will materially adversely affect our business, financial position, or results of operations.

AxoGen and its subsidiaries are not a party to any material litigation as of September 30, 2017.

ITEM 1A - RISK FACTORS

The Company faces a number of risks and uncertainties. In addition to the other information in this report and the Company’s other filings with the SEC, readers should consider carefully the risk factors discussed in Part I “Item 1A. Risk Factors” in the 2016 Annual Report. If any of these risks actually occur, the Company’s business, results of operations or financial condition could be materially adversely affected. There have been no material changes to these risk factors since the filing of the 2016 Annual Report.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Table of Contents

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5 - OTHER INFORMATION

None

Table of Contents

ITEM 6 - EXHIBITS


Exhibit Number		Description

10.1*		Executive Employment Agreement dated as of July 17, 2017, by and between AxoGen Corporation and Jon S. Gingrich (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K/A, filed on July 20, 2017).

10.2*		Form of Non-Qualified Stock Option Inducement Award Agreement to be granted by AxoGen, Inc. to Jon S. Gingrich on July 17, 2017 (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K/A, filed on July 20, 2017).

31.1†		Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Extension Labels Linkbase.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

* Management contract or compensatory plan or arrangement.

† Filed herewith.

†† Furnished herewith.

Table of Contents

EXHIBIT INDEX


Exhibit Number		Description
10.1*		Executive Employment Agreement dated as of July 17, 2017, by and between AxoGen Corporation and Jon S. Gingrich (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K/A, filed on July 20, 2017).

10.2*		Form of Non-Qualified Stock Option Inducement Award Agreement to be granted by AxoGen, Inc. to Jon S. Gingrich on July 17, 2017 (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K/A, filed on July 20, 2017).

31.1†		Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Extension Labels Linkbase.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

* Management contract or compensatory plan or arrangement.

† Filed herewith.

†† Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		AXOGEN, INC.


Dated: November 1, 2017		/s/ Karen Zaderej
		Karen Zaderej
		Chief Executive Officer
		(Principal Executive Officer)


Dated: November 1, 2017		/s/ Peter J. Mariani
		Peter J. Mariani
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 axgn-20170930ex311552310.htm EX-31.1 Ex_311

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Karen Zaderej, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 1, 2017
	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer

EX-31.2 3 axgn-20170930ex312478353.htm EX-31.2 Ex_312

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter J. Mariani, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 1, 2017
	/s/ Peter J. Mariani
	Peter J. Mariani
	Chief Financial Officer

EX-32 4 axgn-20170930xex32.htm EX-32 Ex_32

EXHIBIT 32

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)

In connection with the Quarterly Report on Form 10-Q (the “Report”) of AxoGen, Inc. (the “Company”), Karen Zaderej, Chief Executive Officer of the Company and Peter J. Mariani, Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her/his knowledge that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: November 1, 2017
	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer
	(Principal Executive Officer)


	/s/ Peter J. Mariani
	Peter J. Mariani
	Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 5 axgn-20170930.xml EX-101.INS 0000805928 axgn:AxoGen2010StockIncentivePlanMember 2017-09-30 0000805928 axgn:Axogen2017EmployeeStockPurchasePlanMember 2017-05-24 0000805928 axgn:AxoGen2010StockIncentivePlanMember 2017-05-24 0000805928 us-gaap:EmployeeStockOptionMember axgn:AxoGen2010StockIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-01-01 2017-09-30 0000805928 us-gaap:EmployeeStockOptionMember axgn:AxoGen2010StockIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-09-30 0000805928 axgn:EmployeeConsultantsAndDirectorsStockOptionsMember axgn:AxoGen2010StockIncentivePlanMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0000805928 axgn:EmployeeConsultantsAndDirectorsStockOptionsMember axgn:AxoGen2010StockIncentivePlanMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000805928 axgn:DirectorsAndOfficersStockOptionsMember axgn:AxoGen2010StockIncentivePlanMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0000805928 axgn:DirectorsAndOfficersStockOptionsMember axgn:AxoGen2010StockIncentivePlanMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000805928 axgn:DirectorsAndOfficersStockOptionsMember axgn:AxoGen2010StockIncentivePlanMember 2017-01-01 2017-09-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2017-07-01 2017-09-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2016-07-01 2016-09-30 0000805928 us-gaap:LeaseholdImprovementsMember 2017-09-30 0000805928 us-gaap:EquipmentMember 2017-09-30 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2017-09-30 0000805928 us-gaap:LeaseholdImprovementsMember 2016-12-31 0000805928 us-gaap:EquipmentMember 2016-12-31 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2016-12-31 0000805928 axgn:CommonStockIssuanceOctober2016OfferingAndOverAllotmentOptionMember 2016-10-13 2016-10-13 0000805928 axgn:MidCapLoanMember 2016-10-25 2016-10-25 0000805928 axgn:ThreePeaksLoanMember 2016-10-25 2016-10-25 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember us-gaap:MaximumMember 2016-10-25 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember us-gaap:MinimumMember axgn:OneThreeSevenZeroNineProgressBoulevardAlachuaFlorida32615Member 2017-01-23 2017-01-23 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember us-gaap:MaximumMember axgn:OneThreeSevenZeroNineProgressBoulevardAlachuaFlorida32615Member 2017-01-23 2017-01-23 0000805928 axgn:JaColeMember 2016-10-25 2016-10-25 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember us-gaap:MinimumMember axgn:OneThreeSixThreeOneProgressBoulevardSuite400AlachuaFlorida32615Member 2016-03-16 2016-03-16 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember us-gaap:MaximumMember axgn:OneThreeSixThreeOneProgressBoulevardSuite400AlachuaFlorida32615Member 2016-03-16 2016-03-16 0000805928 2015-01-01 2015-12-31 0000805928 us-gaap:PatentsMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000805928 us-gaap:PatentsMember 2017-09-30 0000805928 us-gaap:LicensingAgreementsMember 2017-09-30 0000805928 us-gaap:PatentsMember 2016-12-31 0000805928 us-gaap:LicensingAgreementsMember 2016-12-31 0000805928 us-gaap:EmployeeStockOptionMember 2017-09-30 0000805928 axgn:Axogen401kPlanMember 2017-07-01 2017-09-30 0000805928 axgn:Axogen401kPlanMember 2017-01-01 2017-09-30 0000805928 axgn:Axogen401kPlanMember 2016-07-01 2016-09-30 0000805928 axgn:Axogen401kPlanMember 2016-01-01 2016-12-31 0000805928 axgn:Axogen401kPlanMember 2016-01-01 2016-09-30 0000805928 us-gaap:LineOfCreditMember 2017-09-30 0000805928 axgn:TermLoanMember 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2016-10-25 0000805928 axgn:ThreePeaksLoanMember us-gaap:LoansPayableMember 2014-11-13 0000805928 axgn:MidCapLoanMember us-gaap:LoansPayableMember 2016-10-25 0000805928 axgn:ThreePeaksLoanMember us-gaap:LoansPayableMember 2014-11-12 0000805928 axgn:MidCapLoanMember us-gaap:LoansPayableMember 2017-01-01 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2017-01-01 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LoansPayableMember 2016-01-01 2016-12-31 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2016-01-01 2016-12-31 0000805928 axgn:ThreePeaksLoanMember us-gaap:LoansPayableMember 2014-11-12 2014-11-12 0000805928 axgn:MidCapLoanMember us-gaap:LoansPayableMember 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2017-09-30 0000805928 us-gaap:CapitalLeaseObligationsMember 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LoansPayableMember 2016-12-31 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2016-12-31 0000805928 us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000805928 us-gaap:OverAllotmentOptionMember 2016-10-13 0000805928 axgn:CommonStockIssuanceOctober2016OfferingAndOverAllotmentOptionMember 2016-10-13 0000805928 us-gaap:OverAllotmentOptionMember 2016-10-07 0000805928 axgn:CommonStockIssuanceOctober2016OfferingMember 2016-10-07 0000805928 2016-09-30 0000805928 2015-12-31 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember axgn:OneThreeSevenZeroNineProgressBoulevardAlachuaFlorida32615Member 2017-01-23 0000805928 2017-07-01 2017-09-30 0000805928 2016-07-01 2016-09-30 0000805928 axgn:ThreePeaksLoanMember 2016-01-01 2016-12-31 0000805928 2016-01-01 2016-09-30 0000805928 us-gaap:EmployeeStockOptionMember axgn:AxoGen2010StockIncentivePlanMember 2017-07-01 2017-09-30 0000805928 us-gaap:EmployeeStockOptionMember axgn:AxoGen2010StockIncentivePlanMember 2017-01-01 2017-09-30 0000805928 us-gaap:EmployeeStockOptionMember axgn:AxoGen2010StockIncentivePlanMember 2016-07-01 2016-09-30 0000805928 us-gaap:EmployeeStockOptionMember axgn:AxoGen2010StockIncentivePlanMember 2016-01-01 2016-09-30 0000805928 2016-12-31 0000805928 2017-10-30 0000805928 2016-01-01 2016-12-31 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember axgn:OneThreeSevenZeroNineProgressBoulevardAlachuaFlorida32615Member 2017-01-23 2017-01-23 0000805928 axgn:TissueProcessingAgreementMember 2015-08-06 2015-08-06 0000805928 axgn:JaColeMember 2013-10-25 2013-10-25 0000805928 axgn:ThreePeaksLoanMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000805928 axgn:CommonStockIssuanceOctober2016OfferingMember 2016-10-07 2016-10-07 0000805928 us-gaap:PatentsMember 2017-01-01 2017-09-30 0000805928 us-gaap:LicensingAgreementsMember 2017-01-01 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2016-10-25 2016-10-25 0000805928 2017-09-30 0000805928 axgn:TissueProcessingAgreementMember 2017-01-01 2017-09-30 0000805928 2017-01-01 2017-09-30 0000805928 axgn:Axogen401kPlanEmployerMatchingContributionTranche2Member 2017-01-01 2017-09-30 0000805928 axgn:Axogen401kPlanEmployerMatchingContributionTranche1Member 2017-01-01 2017-09-30 0000805928 axgn:MidCapLoanMember us-gaap:LineOfCreditMember 2016-10-26 2016-10-26 0000805928 axgn:MidCapLoanMember us-gaap:LoansPayableMember 2016-10-25 2016-10-25 0000805928 us-gaap:CapitalLeaseObligationsMember 2017-01-01 2017-09-30 0000805928 us-gaap:CapitalLeaseObligationsMember 2016-01-01 2016-12-31 0000805928 2016-10-25 2016-10-25 0000805928 axgn:CommonStockIssuanceOctober2016OfferingMember us-gaap:ManagementMember 2016-10-07 0000805928 axgn:JaColeMember 2016-10-25 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember axgn:OneThreeSixThreeOneProgressBoulevardSuite400AlachuaFlorida32615Member 2016-03-16 0000805928 axgn:JaColeMember 2013-10-25 0000805928 axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember 2011-12-31 0000805928 axgn:ThreePeaksLoanMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 2014-11-12 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember axgn:OneThreeSixThreeOneProgressBoulevardSuite400AlachuaFlorida32615Member 2016-03-16 2016-03-16 iso4217:USD xbrli:shares xbrli:shares xbrli:pure axgn:item utr:sqft iso4217:USD P3Y P5Y P12M 151318 2100 7050 2500 5 0.050 P33M P33M P3M P3M 30 0.010 0.030 0.020 0.03 0.02 18 P18M 74000 0.005 0.30 21042240 30000000 2000 25000 10000 15000 12500 461712 P60D P30D 0.0375 1 0.03 0.01 0.0375 P3Y P5Y P5Y P5Y 750000 false --12-31 Q3 2017 2017-09-30 10-Q 0000805928 33456091 Yes Accelerated Filer AxoGen, Inc.

7002165

7072530

3614015

2104119

8052203

10200560

2583459

3606642

1801137

2147976

132474884

136048305

1046364

293575

2491992

919026

272000

335000

95253

136711

95254

747000

31748

136711

46110

48050

16000

60459

19000

5400

11761

10000

1431

46360478

42227825

44037252

39512512

25909500

16003245

30014405

22041097

-9906255

-7973308

<div> <div> 11.  Commitments and Contingencies   Operating Leases   On March 16, 2016, AxoGen entered into the Fourth Amendment to Lease (“Fourth Amendment”) with SNH Medical Office Properties Trust (“SNH”). SNH is the landlord of AC’s currently leased 11,761 square foot corporate headquarters facility at 13631 Progress Boulevard, Suite 400, Alachua, Florida 32615 (the “Current Premises”) pursuant to that certain lease dated as of February 6, 2007, as amended (the “Existing SNH Lease”).  The Fourth Amendment expands the Current Premises by 7,050 square feet (the “Expansion Premises”).  The Fourth Amendment also provides that the Expiration Date (as defined in the Fourth Amendment) of the Existing SNH Lease will be extended to approximately five years from the Occupancy Date (as defined in the Fourth Amendment) which was June 2016.  The original expiration date of the Current Premises remains unchanged; provided, however, that AC shall have the right to extend the Current Premises Term (as defined in the Fourth Amendment) for three additional periods (the “Current Premises Extended Term”), the first such Current Premises Extended Term to commence on November 1, 2018 and end on October 31, 2019, the second such Current Premises Extended Term to commence on November 1, 2019 and end on October 31, 2020, and the third such Current Premises Extended Term to commence on November 1, 2020 and end on the Expiration Date.  AC also has the right to extend the term of the then current Leased Premises (as defined in the Fourth Amendment) for an additional period of five years commencing on the day immediately after the Expiration Date.  AxoGen’s annual cost of such property ranges from approximately $248,000 to $332,000 per year.   On October 25, 2013, AC entered into a commercial lease with Ja-Cole L.P. (“Ja-Cole”). Under the terms of the commercial lease, AxoGen occupied 5,400 square feet of warehouse/office space in its Burleson, Texas Distribution Facility until November 30, 2016 at an annual cost of $43,200. On April 21, 2015, AxoGen entered into a new commercial lease, as amended by the addendum on such date (as amended, the “Ja-Cole Lease”), with Ja-Cole. The new commercial lease superseded and replaced the original lease with Ja-Cole dated October 25, 2013. Under the terms of the Ja-Cole Lease, AxoGen leased an additional 2,100 square feet of warehouse space at the Distribution Facility.   The Ja-Cole Lease is for a three-year term expiring April 21, 2018. On October 25, 2016, AC entered into Commercial Lease Amendment 2 (the “Ja-Cole Amendment”) to the Ja-Cole Lease. Under the terms of the Ja-Cole Amendment, AxoGen leased an additional 2,500 square feet of warehouse/office space at the Distribution Facility.  The Distribution Facility now comprises a total of 10,000 square feet, all of which, pursuant to the Ja-Cole Amendment, will be leased until March 31, 2019.  The annual rental cost of the entire Distribution Facility is now approximately $88,000.  The  Burleson facility  houses raw material storage and product distribution while allowing same day fulfillment of orders for both coasts of the United States.   On January 23, 2017, AC entered into a lease (the “New SNH Lease”) for a five year term commencing April 1, 2017 with SNH Medical Office Properties Trust, a Maryland real estate investment trust (“SNH”), for 1,431 square feet at 13709 Progress Boulevard, Alachua, Florida 32615. Pursuant to the New SNH Lease, AC is to use the space for general office and biomedical research uses. SNH is the landlord of AC’s currently leased corporate headquarters facility at 13631 Progress Boulevard, Alachua, Florida 32615.  AC’s additional annual cost of the Premises range from approximately $25,800 to $29,000 over the life of the lease.   In addition, AxoGen leases space and maintains records at certain other facilities, including the Company’s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.   Estimated future minimum rental payments on the leases are as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Year Ending December 31 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 (9 months ended) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98,835 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 437,900 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 182,250 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 165,116 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 86,638 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:85.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> TOTAL </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 970,739 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Total rent expense for the Company’s leased office and lab space for the nine months ended September 30, 2017 and 2016 was approximately $368,000 and $340,000, respectively.   Service Agreements   From 2009 to February 2016, AxoGen processed and packaged Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia (“LifeNet Health”).  Business requirements of LifeNet Health led to their need for additional space and they notified AxoGen that AxoGen would need to transition out of the Virginia Beach facility on or before February 27, 2016.  On August 6, 2015, AxoGen entered into a License and Services Agreement with Community Blood Center (d/b/a Community Tissue Services) (“CTS”), Dayton, Ohio, an FDA registered tissue establishment.  Processing of the Avance® Nerve Graft pursuant to the CTS agreement began in February 2016.  The CTS agreement is for a five-year term, subject to earlier termination by either party for cause, or after August 6, 2017 without cause, upon 18 months’ notice. Under the CTS agreement, AxoGen pays CTS a facility fee for clean room/manufacturing, storage and office space.  CTS also provides services in support of AxoGen’s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.   In August 2008, the Company entered into an agreement to distribute the AxoGuard® products worldwide in the field of peripheral nerve repair, and the parties subsequently amended the agreement in March, 2012. The agreement expires in August 2022. The Cook Biotech agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforced such provision, and establishes a formula for the transfer cost of the AxoGuard® products. Under the agreement, AxoGen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders.   In December 2011, the Company also entered into a Master Services Agreement for Clinical Research and Related Services.  The Company was required to pay $151,318 upon execution of this agreement and the remainder monthly based on activities associated with the execution of AxoGen’s phase 3 pivotal clinical trial to support a biologics license application (BLA)  for Avance® Nerve Graft.    Certain executive officers of the Company are parties to employment contracts.  Such contracts have severance payments for certain conditions including change of control. <div /></div> </div>

0.01

50000000

2333334

350000

32666

2683334

350000

33008865

33393804

33008865

33393804

330088

333938

4637446

1697443

6697127

2504278

30471881

10689468

42902573

15040400

24311667

57829

4025023

20228815

24378294

42240

4000000

20336054

0.010

0.005

0.0050

0.005

25000000

21000000

58875

21000000

58875

21000000

0.1000

0.0025

0.050

0.0850

0.050

0.0850

0.09

0.045

0.08

0.0350

0.045

0.08

0.085

0.0350

0.05

0.045

0.08

P6Y

P36M

663946

105261

33282

43576

92215

76027

247000

334000

76000

320000

114000

0.03

0.01

263133

346839

-0.29

-0.08

-0.24

-0.06

<div> <div> Earnings (Loss) Per Share of Common Stock   There were no dilutive instruments as of September 30, 2017 and 2016.  The basic and diluted weighted average shares outstanding were 33,286,211 and 30,152,279 shares for the three months ended September 30, 2017 and 2016, respectively, and 33,146,546 and 30,075,715 shares for the nine months ended September 30, 2017 and 2016, respectively.   Basic and diluted net loss per share of common stock for all periods presented is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding and common stock equivalents outstanding, when dilutive.  Potentially dilutive common stock equivalents include shares of common stock which would potentially be issued pursuant to stock warrants and stock options.  Common stock equivalents are not included in determining the fully diluted loss per share if their effect is antidilutive. <div /></div> </div>

9086000

463575

513751

563000

19000

984342

308212

1003512

461712

828979

951473

P3Y

P20Y

P17Y

P20Y

7362063

2481051

10659756

3778612

25061420

9507781

36758263

13541975

864267

70365

2302701

2232090

5727

99367

1036859

1240103

260786

60108

3989000

3255574

5386000

1700000

1089134

1639874

577941

3031528

1631795

<div> <div> 4.    Inventories   Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, Avive® Soft Tissue Membrane, AcroVal® Neurosensory and Motor Testing System, AxoTouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,157,260 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,132,036 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 306,942 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 205,116 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,234,741 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,121,688 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,698,943 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,458,840 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Inventories are net of reserve of approximately $642,000 and $960,000 at September 30, 2017 and December 31, 2016, respectively. <div /></div> </div>

4132036

5157260

5458840

6698943

1121688

1234741

960000

642000

205116

306942

43200

332000

248000

88000

29000

25800

31439329

31675688

46360478

42227825

11081369

11137702

22000

21000000

4000000

10000000

15000000

10000000

6879000

0.005

4025023

4000000

20378294

2800000

8400000

8415096

1421834

5310

20899

21596

20265745

20356698

<div> <div> 8.    Term Loan Agreements and Long-Term Debt   Term Loan Agreement and Long Term Debt consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Term Loan Agreement with MidCap Financial Trust (“MidCap”) for a total of $21,000,000, net of $663,946 of unamortized deferred financing fees at September 30, 2017, and $771,185 at December 31, 2016. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 8.5% rate.  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,336,054 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,228,815 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Revolving Loan Agreement with MidCap for up to $10,000,000 with borrowings based upon eligible accounts receivable and inventory. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 5.0% rate. </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,000,000 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,025,023 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equipment Lease Agreement with Cisco Capital for a total lease amount of $58,875 which has a 36 month term and requires no lease payments for the first three months of the lease and 33 equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at 3.5% per annum. </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,240 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 57,829 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,378,294 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,311,667 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less current revolving loan </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4,000,000) </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4,025,023) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less current maturities of long term debt </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (21,596) </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (20,899) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Long-term portion </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,356,698 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,265,745 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Credit Facilities   Three Peaks Term Loan Agreement and Revenue Interest Agreement   On November 12, 2014, AxoGen, as borrower, and AC, as guarantor, entered into that certain Term Loan Agreement (the “Three Peaks Term Loan Agreement”), dated November 12, 2014, by and among AxoGen, as borrower, AC, as guarantor, the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP, as administrative and collateral agent for the lenders. Under the Three Peaks Term Loan Agreement, Three Peaks provided AxoGen a term loan of $25 million which had a six-year term and required interest only payments and a final principal payment due at the end of the term. Interest was payable quarterly at 9.0% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 resulted in a 10% rate.   In addition, on November 12, 2014, AxoGen entered into that certain Revenue Interest Agreement (the “Revenue Interest Agreement”) with Three Peaks. Royalty payments were based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12-month period.   On October 26, 2016, the Three Peaks Term Loan Agreement and Revenue Interest Agreement were paid in full and the Company had no further obligations pursuant to such agreements.   MidCap Term Loan Agreement   On October 25, 2016 (the “Closing Date”), AxoGen and AC, each as borrowers, entered into a Credit and Security Agreement (Term Loan) (the ''MC Term Loan Agreement") with the lenders party thereto and MidCap Financial Trust (“MidCap”), as administrative agent and a lender. Under the MC Term Loan Agreement, MidCap provided the Company a term loan in the aggregate principal amount of $21 million (the "Term Loan") which has a maturity date of May 1, 2021 and requires interest only payments through December 1, 2018, and thereafter, 30 monthly payments of principal and interest resulting in the Term Loan being fully paid by the maturity date. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5%. In addition to the interest charged on the Term Loan, the Company is also obligated to pay certain fees, including an annual agency fee of 0.25% of the aggregate principal amount of the Term Loan.   The Company has the option at any time to prepay the Term Loan in whole or in part, subject to certain conditions, a prepayment fee, and a 5.0% exit fee as specified in the MC Term Loan Agreement. The prepayment fee is determined by multiplying the amount being prepaid by the following applicable percentage amount: (a) 3.0% during the first year following the Closing Date; (b) 2.0% during the second year following the Closing Date, and (c) 1.0% thereafter. However, no prepayment fee is due in the event the prepayment is a result of refinancing the Term Loan and Revolving Loan with MidCap or an affiliate of MidCap.    MidCap Revolving Loan Agreement   In addition, on October 25, 2016, AxoGen and AC, each as borrowers, also entered into a Credit and Security Agreement (Revolving Loan) (the ''Revolving Loan Agreement") with the lenders party thereto and MidCap, as administrative agent and a lender.  Under the Revolving Loan Agreement, MidCap agreed to lend to the Company up to $10 million under a revolving credit facility (the "Revolving Loan") which amount may be drawn down by the Company based upon an available borrowing base which includes certain accounts receivable and inventory.  The Revolving Loan may be increased to up to $15 million at the Company’s request and with the approval of MidCap. The maturity date of the Revolving Loan is May 1, 2021. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% on outstanding advances. In addition to the interest charged on the Revolving Loan, the Company is also obligated to pay certain fees, including a collateral management fee of 0.5% per annum of the principal amount outstanding on the Revolving Loan from time to time and an unused line fee of 0.5% per annum on the difference between the average amount outstanding on the Revolving Loan minus the total amount of the Revolving Loan commitment. The Revolving Loan is subject to a minimum balance, such that the Company pays the greater of: (i) interest accrued on the actual amount drawn under the Revolving Loan Facility; and (ii) interest accrued on 30% of the average borrowing base.  If the Revolving Loan is terminated or permanently reduced prior to the maturity date, MidCap is owed a deferred revolving loan origination fee as specified in the Revolving Loan Agreement.  No deferred revolving loan origination fee is due in the event the Revolving Loan is paid in full or the termination of the revolving credit facility is a result of refinancing the Term Loan and Revolving Loan with MidCap or an affiliate of MidCap.      The MC Term Loan Agreement and the Revolving Loan Agreement each contain covenants that place restrictions on AxoGen’s operations, including, without limitation, covenants related to debt restrictions, investment restrictions, dividend restrictions, restrictions on transactions with affiliates and certain revenue covenants. MidCap, on behalf of the lenders under the agreements, has a first perfected security interest in the assets of the Company to guarantee the payment in full of the agreements. Upon the payment in full to MidCap and the lenders of the Term Loan Agreement and Revolving Loan Agreement, the Company would have no further obligations to MidCap or the lenders under the Term Loan Agreement or the Revolving Loan Agreement.  As of September 30, 2017, we were in compliance with the loan covenants.   The Company used the aggregate proceeds of $25 million from the Term Loan and the Revolving Loan to pay the outstanding indebtedness owed to Three Peaks and the other lenders to terminate the Three Peaks Term Loan Agreement and the Revenue Interest Agreement.  Expenses and fees of approximately $800,000 to complete the negotiation and documentation of the Term Loan and the Revolving Loan and prepayment fees of approximately $2.3 million owed to Three Peaks were paid from the Company’s own funds.   Interest expense for the year ended December 31, 2016 was approximately $5,386,000 compared to $3,989,000 for the year ended December 31, 2015.  The 2016 amount includes a final payment to Three Peaks of approximately $2,447,000 inclusive of prepayment fees and accrued interest through October 25, 2016. In addition, as a result of the accounting treatment for the Three Peaks transaction, the Company had previously recorded a total of $747,000 of deferred interest charges which were offset against these prepayment fees.  The net impact of these transactions resulted in a net interest charge of approximately $1,700,000 in the year which was included in interest expense for the year ended December 31, 2016.  Additionally, as the result of the extinguishment of the debt facility with Three Peaks, the Company wrote off approximately $750,000 of prepaid financing fees to interest expense – deferred financing costs in 2016.   As of September 30, 2017, the Term Loan had an outstanding balance of $21.0 million, with an interest rate of 8.5%.  Also, at September 30, 2017, the borrowing base under the Revolving Loan Agreement was approximately $6,879,000 and the Company had an outstanding balance on the Revolving Loan facility of $4,000,000 with an interest rate of 5.0%.    Annual maturities of the Company’s long-term obligations are as follows:    <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Year Ending December 31 </td> <td colspan="2" valign="bottom" style="width:19.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,310 </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,421,834 </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,415,096 </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,400,000 </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,800,000 </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,042,240 </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less unamortized debt issuance costs </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (663,946) </td> </tr> <tr> <td valign="bottom" style="width:80.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> TOTAL </td> <td valign="bottom" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:15.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,378,294 </td> </tr> </table></div>   <div /></div> </div>

645864

1015195

-770465

-799385

-9781654

-8189118

-8784160

-2305373

-7946283

-2124079

<div> <div> Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period.  The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the adoption date.  During the quarter ended September 30, 2017, we completed the evaluation of the new standard and a related assessment and review of a representative sample of existing revenue contracts with our customers on our most significant revenue streams. Based upon this assessment, we do not believe there will be a material change to the timing of our revenue recognition. However, during the fourth quarter of 2017 we will continue our preparation for adopting the standard and periodically brief our Audit Committee on our progress. It is likely we will be required to provide additional disclosures in the notes to the consolidated financial statements upon adoption. We have not yet determined the effect of the ASU on our internal control over financial reporting or other changes in business practices and processes but will do so in the design and implementation phase to occur during the remainder of 2017. Additionally, we have not made a decision on which adoption method to utilize. Our evaluation of ASU 2014-09 is ongoing.   In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements.   In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230). The ASU was issued intending to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this standard will have a material impact on our consolidated financial statements.   In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), guidance that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new guidance is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this guidance will have a material impact on our Statement of Cash Flows.     In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting.”  ASU 2017-09 provides clarity on which changes to the terms or conditions of share-based payment awards require entities to apply the modification accounting provisions required in Topic 718.  ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued.  The Company does not expect that the adoption of ASU 2017-09 will have a material impact on the Company’s results of operations and financial condition.   The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures <div /></div> </div>

-3373699

-1123686

-1801973

-625654

-5410461

-1181687

-6144310

-1498425

970739

98835

86638

165116

182250

437900

340000

368000

804691

1361769

-22871

-2804

-25388

-1603

199124

2300000

800000

29472

157491

182953

612974

616432

511804

571912

18670000

25000000

41553210

645864

1085279

1270173

1577561

447650

1436733

1763764

711319

1494247

1763840

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,436,733 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,270,173 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 711,319 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 447,650 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Processing equipment </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,763,764 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,577,561 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,147,976) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,801,137) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Property and equipment, net </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,763,840 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,494,247 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

80934

83733

41578233

2447000

15589

3033521

1118358

4727551

1795292

-117883823

-125830106

29698866

11205224

43455390

16046253

583000

214000

860000

319000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,104,119 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,614,015 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,361,769 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 804,691 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,606,642 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,583,459 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts Payable and Accrued Expenses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,072,530 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,002,165 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Term Loan Agreement with MidCap Financial Trust (“MidCap”) for a total of $21,000,000, net of $663,946 of unamortized deferred financing fees at September 30, 2017, and $771,185 at December 31, 2016. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 8.5% rate.  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,336,054 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,228,815 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Revolving Loan Agreement with MidCap for up to $10,000,000 with borrowings based upon eligible accounts receivable and inventory. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 5.0% rate. </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,000,000 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,025,023 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equipment Lease Agreement with Cisco Capital for a total lease amount of $58,875 which has a 36 month term and requires no lease payments for the first three months of the lease and 33 equal payments of principal and interest until the end of the term.  Interest on the lease is payable monthly at 3.5% per annum. </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,240 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 57,829 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,378,294 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24,311,667 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less current revolving loan </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4,000,000) </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4,025,023) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less current maturities of long term debt </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (21,596) </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (20,899) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Long-term portion </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,356,698 </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,265,745 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> License agreements </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,003,512 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 984,342 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Patents </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 461,712 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 308,212 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated amortization </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (513,751) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (463,575) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:68.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intangible assets, net </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 951,473 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 828,979 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,157,260 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,132,036 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 306,942 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 205,116 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,234,741 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,121,688 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Inventories </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,698,943 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,458,840 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine months ended September 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.16 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.00 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50.72 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61.71 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.07 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.22 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   <div /></div> </div>

20076297

7090059

27515266

9466496

1046364

2491992

P1Y

P4Y

P3Y

P10Y

P7Y

P3Y

0.25

0.125

P4Y

P6Y1M28D

0.6171

0.5072

0.01220

0.02070

7700000

600000

5500000

635525

3.00

6.77

7.50

<div> <div> 3.    Summary of Significant Accounting Policies   Revenue Recognition   Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user.  Revenues from research grants are recognized in the period the associated costs are incurred.   Cash and Cash Equivalents and Concentration   For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.   Accounts Receivable and Concentration of Credit Risk   Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.   We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The allowance for doubtful accounts reserve balance was approximately $335,000 and $272,000 at September 30, 2017 and December 31, 2016, respectively.   Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.   Inventories   Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, Avive® Soft Tissue Membrane, AcroVal® Neurosensory and Motor Testing System, AxoTouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or market.   We regularly review the inventory status to determine the expected reserve level required.  The Company policy is to monitor the shelf life of its products and reserve amounts based on the expiration date of the finished goods inventory.  We also reserve a portion of raw materials based on our historical experience of tissue that fails during the inspection and debridement stage due to medical history, serology compliance or poor quality.    Income Taxes   The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.   The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2014 through 2016; however, there currently are no examinations in process.   Fair Value of Financial Instruments   The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.    Share-Based Compensation   The Company measures all employee stock-based compensation awards using a fair value method and records such expense in its consolidated financial statements. The estimated value of the portion of the award that is ultimately expected to vest, taking into consideration estimated forfeitures based on the Company’s historical forfeiture rate, is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the grant date fair value of stock option awards generally on the date of grant using the Black-Scholes option pricing model.   With respect to performance stock units (“PSUs”), the number of shares that vest and are issued to the recipient is based upon the Company’s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company’s closing stock price on the grant date and its estimate of achieving such performance targets. See further discussion and disclosures in Note 9: “Stock Incentive Plan.”   Use of Estimates   The preparation of consolidated financial statements in conformity with USGAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.   Earnings (Loss) Per Share of Common Stock   There were no dilutive instruments as of September 30, 2017 and 2016.  The basic and diluted weighted average shares outstanding were 33,286,211 and 30,152,279 shares for the three months ended September 30, 2017 and 2016, respectively, and 33,146,546 and 30,075,715 shares for the nine months ended September 30, 2017 and 2016, respectively.   Basic and diluted net loss per share of common stock for all periods presented is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding and common stock equivalents outstanding, when dilutive.  Potentially dilutive common stock equivalents include shares of common stock which would potentially be issued pursuant to stock warrants and stock options.  Common stock equivalents are not included in determining the fully diluted loss per share if their effect is antidilutive.   Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period.  The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the adoption date.  During the quarter ended September 30, 2017, we completed the evaluation of the new standard and a related assessment and review of a representative sample of existing revenue contracts with our customers on our most significant revenue streams. Based upon this assessment, we do not believe there will be a material change to the timing of our revenue recognition. However, during the fourth quarter of 2017 we will continue our preparation for adopting the standard and periodically brief our Audit Committee on our progress. It is likely we will be required to provide additional disclosures in the notes to the consolidated financial statements upon adoption. We have not yet determined the effect of the ASU on our internal control over financial reporting or other changes in business practices and processes but will do so in the design and implementation phase to occur during the remainder of 2017. Additionally, we have not made a decision on which adoption method to utilize. Our evaluation of ASU 2014-09 is ongoing.   In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements.   In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230). The ASU was issued intending to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this standard will have a material impact on our consolidated financial statements.   In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), guidance that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new guidance is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this guidance will have a material impact on our Statement of Cash Flows.     In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting.”  ASU 2017-09 provides clarity on which changes to the terms or conditions of share-based payment awards require entities to apply the modification accounting provisions required in Topic 718.  ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued.  The Company does not expect that the adoption of ASU 2017-09 will have a material impact on the Company’s results of operations and financial condition.   The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures. <div /></div> </div>

14921149

10552137

<div> <div> 10.   Public Offering of Common Stock   On October 7, 2016, AxoGen entered into an underwriting agreement with JMP Securities LLC, as representative of the several underwriters (collectively, the “Underwriters”), to issue and sell 2,333,334 shares of the Company’s common stock in an underwritten registered public offering (the “2016 Offering”) at an offering price of $7.50 per share.  Pursuant to the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 350,000 shares of common stock, which the underwriters exercised in full on October 7, 2016.  Five of the Company’s directors and officers purchased an aggregate of approximately 32,666 shares of common stock in the 2016 Offering and such purchases were made on the same terms and conditions as purchases by the public in the 2016 Offering. The 2016 Offering closed on October 13, 2016, and the Company received net proceeds of approximately $18.67 million from the sale of 2,683,334 shares of common stock, which includes the additional 350,000 shares of common stock, after deducting the underwriting discounts and commissions and estimated offering expenses. <div /></div> </div>

771185

663946

30075715

30152279

33146546

33286211

EX-101.SCH 6 axgn-20170930.xsd EX-101.SCH 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Intangible Assets - Components of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Term Loan Agreements and Long Term Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40806 - Disclosure - Term Loan Agreements and Long Term Debt - Annual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Commitments and Contingencies - Estimated Future Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Term Loan Agreements and Long Term Debt link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock Incentive Plan link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Public Offering of Common Stock link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Term Loan Agreements and Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Intangible Assets - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Term Loan Agreements and Long Term Debt - Schedule of Debt - Terms (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revenue Interest Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revolving Loan (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Term Loan Agreements and Long Term Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock Incentive Plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stock Incentive Plan - Summary of Weighted-Average Assumptions Used for Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Public Offering of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Commitments and Contingencies - Service Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Retirement Plan (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axgn-20170930_cal.xml EX-101.CAL EX-101.DEF 8 axgn-20170930_def.xml EX-101.DEF EX-101.LAB 9 axgn-20170930_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of year Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of approximately $54,000 and $59,000, respectively Accounts receivable, net of allowance for doubtful accounts of approximately $335,000 and $272,000, respectively Inventory, Net Inventory Inventory, net Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Finite-Lived Intangible Assets, Net Intangible assets Intangible assets, net Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity Liabilities, Current [Abstract] Current liabilities: Line of Credit, Current Less current revolving loan Borrowings under revolving loan agreement Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts Payable and Accrued Expenses Long-term Debt, Current Maturities Less current maturities of long term debt Current maturities of long term obligations Deferred Revenue, Current Deferred revenue, current Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long Term Obligations, net of current maturities and deferred financing fees Long-term portion Deferred Rent Credit, Noncurrent Deferred lease Deferred Revenue, Noncurrent Deferred revenue, noncurrent Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity: Common Stock, Value, Issued Common stock, $0.01 par value per share; 50,000,000 shares authorized; 33,393,804 and 33,008,865 shares issued and outstanding Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total shareholders' equity Liabilities and Equity Total Liabilities and Shareholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Allowance for doubtful accounts reserve balance Common Stock, Par or Stated Value Per Share Common stock, par value Par value of common stock Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Shares of common stock sold Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Revenues Revenues Cost of Goods Sold Cost of goods sold Gross Profit Gross profit Costs and Expenses [Abstract] Costs and expenses: Selling and Marketing Expense. Sales and marketing Research and Development Expense Research and development General and Administrative Expense General and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Expense Interest expense Amortization of Financing Costs and Discounts Interest expense-deferred financing costs Other Nonoperating Income (Expense) Other (expense) Nonoperating Income (Expense) Total other income (expense) Net Loss Net loss Net Loss Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted Average Common Shares outstanding - basic and diluted Earnings Per Share, Basic and Diluted Loss Per Common share - basic and diluted (in dollars per share) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Depreciation Amortization of Intangible Assets Amortization of intangible assets Amortization of deferred financing costs Amortization of deferred financing costs Represents the write off of deferred financing costs. Write Off Of Deferred Financing Costs Write off of deferred financing costs Provision for Doubtful Accounts Provision for bad debt Share-based Compensation Stock-based compensation Paid-in-Kind Interest Interest added to note payable Increase (Decrease) in Operating Capital [Abstract] Change in assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Liabilities Deferred liabiliies Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used for operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Intangible Assets Acquisition of intangible assets Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used for investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from Lines of Credit Borrowings on revolving loan Repayments of Lines of Credit Payments on revolving loan Proceeds from Issuance of Long-term Debt Proceeds from issuance of debt Repayments of Long-term Debt Repayments of long-term debt Payments of Debt Issuance Costs Debt issuance costs Debt issuance costs Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow activity: Interest Paid Cash paid for interest Basis of Presentation Basis of Accounting [Text Block] Basis of Presentation Organization and Business Nature of Operations [Text Block] Organization and Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Inventories Inventory Disclosure [Text Block] Inventories Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Term Loan Agreements and Long Term Debt Long-term Debt [Text Block] Term Loan Agreements and Long Term Debt Stock Incentive Plan Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plan Public Offering of Common Stock Stockholders' Equity Note Disclosure [Text Block] Public Offering of Common Stock Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Retirement Plan Pension and Other Postretirement Benefits Disclosure [Text Block] Retirement Plan Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents and Concentration Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts Receivable and Concentration of Credit Risk Inventory, Policy [Policy Text Block] Inventories Income Tax, Policy [Policy Text Block] Income Taxes Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Use of Estimates, Policy [Policy Text Block] Use of Estimates Earnings Per Share, Policy [Policy Text Block] Earnings (Loss) Per Share of Common Stock New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Inventory, Current [Table Text Block] Schedule of inventories Property, Plant and Equipment [Table Text Block] Schedule of Property and equipment Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expenses Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Term Loan Agreements and Long Term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of Maturities of Long Term Debt Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions for options granted Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of estimated future minimum rental payments Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Represents the reserve for accounts deemed uncollectible, expressed as a percentage. Reserve for Accounts Receivable Deemed Uncollectible Percentage Reserve for accounts deemed uncollectible (as a percent) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Earnings (Loss) Per Share of Common Stock Weighted Average Number Diluted Shares Outstanding Adjustment Dilutive instruments outstanding Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Work in Process, Net of Reserves Work in process Inventory, Raw Materials, Net of Reserves Raw materials Inventory Valuation Reserves Inventory valuation reserves Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Equipment and tangible personal property commonly used in offices. Furniture And Office Equipment [Member] Furniture and Equipment Leasehold Improvements [Member] Leasehold Improvements Equipment [Member] Processing Equipment Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Gross Property and equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] License Agreements Patents [Member] Patents Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Finite-Lived Intangible Assets [Line Items] Intangible assets Intangible assets consist of: Finite-Lived Intangible Assets, Gross Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Accumulated Amortization Less: accumulated amortization Finite-Lived Intangible Assets, Remaining Amortization Period Amortization period of intangible assets License Costs Patent costs Represents capitalized costs related to patents that are pending, not currently subject to amortization. Amount is included in total of finite lived intangible assets gross. Nonamortizable Pending Patent Costs Non-amortizable pending costs Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Future amortization of license and patent agreements Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Remainder of this year Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year, and through the fifth fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Finite Lived Intangible Assets, Amortization Expense, Year Two Through Year Five Next five years Finite-Lived Intangible Assets, Amortization Expense, after Year Five After year five Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling And Marketing Expense [Member] Sales and Marketing Expense Notice period for termination of license agreements. Notice Period for Termination of License Agreements License agreements extended period Royalty fees percentage under license agreements. Royalty Fees Percentage under License Agreements Royalty fees range under the license agreements Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements. Minimum Royalty of License Agreement Minimum royalty of agreements The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements. Percentage of Capping Royalties for Multiple Royalty Payments to Licensors Royalty stack cap for royalties paid to more than one licensor for sales of the same product Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement. Milestone Payment Contingent upon Receipt of Grant Milestone fee upon receiving a Phase II Small Business Innovation Research Represents the amount of milestone payment due if AxoGen receives FDA approval of its Avance® Nerve Graft. Milestone Payment Contingent Upon F D A Approval Milestone fee upon FDA approval Represents the amount of milestone payment due upon first commercial use of certain licensed technology to provide services to manufacture products for third parties. Milestone Payment Contingent Upon First Commercial Use of Certain Licensed Technology Milestone fee upon first commercial use of certain licensed technology Represents the amount of milestone payment due upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products. Milestone Payment Contingent Upon First Use to Manufacture Products Utilizing Certain Technology Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products Royalty Expense Royalty fees included in sales and marketing expense Accounts Payable and Accrued Liabilities Accounts Payable, Current Accounts payable Miscellaneous Accruals Current Accrued expenses Accrued Compensation Current Accrued compensation Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] EX-101.PRE 10 axgn-20170930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 30, 2017
Document and Entity Information
Entity Registrant Name	AxoGen, Inc.
Entity Central Index Key	0000805928
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		33,456,091
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 22,041,097	$ 30,014,405
Accounts receivable, net of allowance for doubtful accounts of approximately $335,000 and $272,000, respectively	10,200,560	8,052,203
Inventory	6,698,943	5,458,840
Prepaid expenses and other	571,912	511,804
Total current assets	39,512,512	44,037,252
Property and equipment, net	1,763,840	1,494,247
Intangible assets	951,473	828,979
Total Assets	42,227,825	46,360,478
Current liabilities:
Borrowings under revolving loan agreement	4,000,000	4,025,023
Accounts payable and accrued expenses	7,072,530	7,002,165
Current maturities of long term obligations	21,596	20,899
Deferred revenue, current	43,576	33,282
Total current liabilities	11,137,702	11,081,369
Long Term Obligations, net of current maturities and deferred financing fees	20,356,698	20,265,745
Deferred lease	105,261
Deferred revenue, noncurrent	76,027	92,215
Total liabilities	31,675,688	31,439,329
Shareholders' equity:
Common stock, $0.01 par value per share; 50,000,000 shares authorized; 33,393,804 and 33,008,865 shares issued and outstanding	333,938	330,088
Additional paid-in capital	136,048,305	132,474,884
Accumulated deficit	(125,830,106)	(117,883,823)
Total shareholders' equity	10,552,137	14,921,149
Total Liabilities and Shareholders' equity	$ 42,227,825	$ 46,360,478

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 335,000	$ 272,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	33,393,804	33,008,865
Common stock, shares outstanding	33,393,804	33,008,865

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidated Statements of Operations
Revenues	$ 16,046,253	$ 11,205,224	$ 43,455,390	$ 29,698,866
Cost of goods sold	2,504,278	1,697,443	6,697,127	4,637,446
Gross profit	13,541,975	9,507,781	36,758,263	25,061,420
Costs and expenses:
Sales and marketing	9,466,496	7,090,059	27,515,266	20,076,297
Research and development	1,795,292	1,118,358	4,727,551	3,033,521
General and administrative	3,778,612	2,481,051	10,659,756	7,362,063
Total costs and expenses	15,040,400	10,689,468	42,902,573	30,471,881
Loss from operations	(1,498,425)	(1,181,687)	(6,144,310)	(5,410,461)
Other income (expense):
Interest expense	(577,941)	(1,089,134)	(1,639,874)	(3,255,574)
Interest expense-deferred financing costs	(46,110)	(31,748)	(136,711)	(95,254)
Other (expense)	(1,603)	(2,804)	(25,388)	(22,871)
Total other income (expense)	(625,654)	(1,123,686)	(1,801,973)	(3,373,699)
Net Loss	$ (2,124,079)	$ (2,305,373)	$ (7,946,283)	$ (8,784,160)
Weighted Average Common Shares outstanding - basic and diluted	33,286,211	30,152,279	33,146,546	30,075,715
Loss Per Common share - basic and diluted (in dollars per share)	$ (0.06)	$ (0.08)	$ (0.24)	$ (0.29)

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (7,946,283)	$ (8,784,160)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	346,839	263,133
Amortization of intangible assets	60,459	48,050
Amortization of deferred financing costs	136,711	95,253
Provision for bad debt	83,733	80,934
Stock-based compensation	2,491,992	1,046,364
Interest added to note payable		199,124
Change in assets and liabilities:
Accounts receivable	(2,232,090)	(2,302,701)
Inventory	(1,240,103)	(1,036,859)
Prepaid expenses and other	(60,108)	(260,786)
Accounts payable and accrued expenses	70,365	864,267
Deferred liabiliies	99,367	5,727
Net cash used for operating activities	(8,189,118)	(9,781,654)
Cash flows from investing activities:
Purchase of property and equipment	(616,432)	(612,974)
Acquisition of intangible assets	(182,953)	(157,491)
Net cash used for investing activities	(799,385)	(770,465)
Cash flows from financing activities:
Borrowings on revolving loan	41,553,210
Payments on revolving loan	(41,578,233)
Repayments of long-term debt	(15,589)
Debt issuance costs	(29,472)
Proceeds from exercise of stock options	1,085,279	645,864
Net cash provided by financing activities	1,015,195	645,864
Net decrease in cash and cash equivalents	(7,973,308)	(9,906,255)
Cash and cash equivalents, beginning of year	30,014,405	25,909,500
Cash and cash equivalents, end of period	22,041,097	16,003,245
Supplemental disclosures of cash flow activity:
Cash paid for interest	$ 1,631,795	$ 3,031,528

XML 16 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2017
Basis of Presentation
Basis of Presentation	1. Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiaries, AxoGen Corporation (“AC”) and AxoGen Europe GmbH, established in the fourth quarter of 2016, as of September 30, 2017 and December 31, 2016 and for the three and nine month periods ended September 30, 2017 and 2016. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“USGAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2016, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2016. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2017
Organization and Business
Organization and Business	2. Organization and Business Business Summary We are a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries. Avance® Nerve Graft and Avive® Soft Tissue Membrane are processed in the United States by AxoGen at its processing facility in Dayton, Ohio. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated and are distributed worldwide exclusively by AxoGen. The AcroVal® Neurosensory and Motor Testing System and AxoTouch® Two Point Discriminator are contract manufactured by Viron Technologies, LLC. (formerly Cybernetics Research Laboratories) (“Viron”) Tucson, Arizona. Viron supplies the AcroVal® and AxoTouch® unpackaged and they are packaged at AxoGen’s distribution facility in Burleson, Texas. AxoGen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiary, AC.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred. Cash and Cash Equivalents and Concentration For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents. Accounts Receivable and Concentration of Credit Risk Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The allowance for doubtful accounts reserve balance was approximately $335,000 and $272,000 at September 30, 2017 and December 31, 2016, respectively. Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures. Inventories Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, Avive® Soft Tissue Membrane, AcroVal® Neurosensory and Motor Testing System, AxoTouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or market. We regularly review the inventory status to determine the expected reserve level required. The Company policy is to monitor the shelf life of its products and reserve amounts based on the expiration date of the finished goods inventory. We also reserve a portion of raw materials based on our historical experience of tissue that fails during the inspection and debridement stage due to medical history, serology compliance or poor quality. Income Taxes The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership. The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2014 through 2016; however, there currently are no examinations in process. Fair Value of Financial Instruments The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company. Share-Based Compensation The Company measures all employee stock-based compensation awards using a fair value method and records such expense in its consolidated financial statements. The estimated value of the portion of the award that is ultimately expected to vest, taking into consideration estimated forfeitures based on the Company’s historical forfeiture rate, is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the grant date fair value of stock option awards generally on the date of grant using the Black-Scholes option pricing model. With respect to performance stock units (“PSUs”), the number of shares that vest and are issued to the recipient is based upon the Company’s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company’s closing stock price on the grant date and its estimate of achieving such performance targets. See further discussion and disclosures in Note 9: “Stock Incentive Plan.” Use of Estimates The preparation of consolidated financial statements in conformity with USGAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Earnings (Loss) Per Share of Common Stock There were no dilutive instruments as of September 30, 2017 and 2016. The basic and diluted weighted average shares outstanding were 33,286,211 and 30,152,279 shares for the three months ended September 30, 2017 and 2016, respectively, and 33,146,546 and 30,075,715 shares for the nine months ended September 30, 2017 and 2016, respectively. Basic and diluted net loss per share of common stock for all periods presented is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding and common stock equivalents outstanding, when dilutive. Potentially dilutive common stock equivalents include shares of common stock which would potentially be issued pursuant to stock warrants and stock options. Common stock equivalents are not included in determining the fully diluted loss per share if their effect is antidilutive. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the adoption date. During the quarter ended September 30, 2017, we completed the evaluation of the new standard and a related assessment and review of a representative sample of existing revenue contracts with our customers on our most significant revenue streams. Based upon this assessment, we do not believe there will be a material change to the timing of our revenue recognition. However, during the fourth quarter of 2017 we will continue our preparation for adopting the standard and periodically brief our Audit Committee on our progress. It is likely we will be required to provide additional disclosures in the notes to the consolidated financial statements upon adoption. We have not yet determined the effect of the ASU on our internal control over financial reporting or other changes in business practices and processes but will do so in the design and implementation phase to occur during the remainder of 2017. Additionally, we have not made a decision on which adoption method to utilize. Our evaluation of ASU 2014-09 is ongoing. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230). The ASU was issued intending to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this standard will have a material impact on our consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), guidance that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new guidance is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this guidance will have a material impact on our Statement of Cash Flows. In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting.” ASU 2017-09 provides clarity on which changes to the terms or conditions of share-based payment awards require entities to apply the modification accounting provisions required in Topic 718. ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company does not expect that the adoption of ASU 2017-09 will have a material impact on the Company’s results of operations and financial condition. The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2017

Inventories

Inventories

4. Inventories


	September 30,		December 31,
	2017		2016

Finished goods	$	5,157,260	$	4,132,036
Work in process		306,942		205,116
Raw materials		1,234,741		1,121,688
Inventories	$	6,698,943	$	5,458,840

Inventories are net of reserve of approximately $642,000 and $960,000 at September 30, 2017 and December 31, 2016, respectively.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Property and Equipment

9 Months Ended

Sep. 30, 2017

Property and Equipment

Property and Equipment

5. Property and Equipment

Property and equipment consist of the following:


	September 30,		December 31,
	2017		2016

Furniture and equipment	$	1,436,733	$	1,270,173
Leasehold improvements		711,319		447,650
Processing equipment		1,763,764		1,577,561
Less: accumulated depreciation and amortization		(2,147,976)		(1,801,137)
Property and equipment, net	$	1,763,840	$	1,494,247

XML 21 R11.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2017

Intangible Assets

Intangible Assets

6. Intangible Assets

The Company’s intangible assets consist of the following:


	September 30,		December 31,
	2017		2016

License agreements	$	1,003,512	$	984,342
Patents		461,712		308,212
Less: accumulated amortization		(513,751)		(463,575)
Intangible assets, net	$	951,473	$	828,979

License agreements are being amortized over periods ranging from 17-20 years. Patent costs of $22,000 were being amortized over three years. As of September 30, 2017, those patents were fully amortized, and the remaining patents of $461,712 are pending patent costs and are being amortized over periods up to 20 years. Amortization expense was approximately $19,000 and $16,000 for the three months ended September 30, 2017 and 2016, respectively, and approximately $60,000 and $48,000 for the nine months ended September 30, 2017 and 2016, respectively. As of September 30, 2017, future amortization of license agreements and patents (i) for the remainder of fiscal year 2017 is $19,000, (ii) for the fiscal years 2018 through 2022 is expected to be $74,000 per year, and (iii) after 2022 an aggregate $563,000.

License Agreements

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

XML 22 R12.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2017

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

7. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:


	September 30,		December 31,
	2017		2016

Accounts payable	$	2,104,119	$	3,614,015
Accrued expenses		1,361,769		804,691
Accrued compensation		3,606,642		2,583,459
Accounts Payable and Accrued Expenses	$	7,072,530	$	7,002,165

XML 23 R13.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt

9 Months Ended

Sep. 30, 2017

Term Loan Agreements and Long Term Debt

Term Loan Agreements and Long Term Debt

8. Term Loan Agreements and Long-Term Debt

Term Loan Agreement and Long Term Debt consist of the following:


	September 30,		December 31,
	2017		2016

Term Loan Agreement with MidCap Financial Trust (“MidCap”) for a total of $21,000,000, net of $663,946 of unamortized deferred financing fees at September 30, 2017, and $771,185 at December 31, 2016. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 8.5% rate.	$	20,336,054	$	20,228,815

Revolving Loan Agreement with MidCap for up to $10,000,000 with borrowings based upon eligible accounts receivable and inventory. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 5.0% rate.		4,000,000		4,025,023

Equipment Lease Agreement with Cisco Capital for a total lease amount of $58,875 which has a 36 month term and requires no lease payments for the first three months of the lease and 33 equal payments of principal and interest until the end of the term. Interest on the lease is payable monthly at 3.5% per annum.		42,240		57,829
Total		24,378,294		24,311,667
Less current revolving loan		(4,000,000)		(4,025,023)
Less current maturities of long term debt		(21,596)		(20,899)
Long-term portion	$	20,356,698	$	20,265,745

Credit Facilities

Three Peaks Term Loan Agreement and Revenue Interest Agreement

On October 26, 2016, the Three Peaks Term Loan Agreement and Revenue Interest Agreement were paid in full and the Company had no further obligations pursuant to such agreements.

MidCap Term Loan Agreement

MidCap Revolving Loan Agreement

Annual maturities of the Company’s long-term obligations are as follows:


Year Ending December 31	Amount
2017	$	5,310
2018		1,421,834
2019		8,415,096
2020		8,400,000
2021		2,800,000
		21,042,240
Less unamortized debt issuance costs		(663,946)
TOTAL	$	20,378,294

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan

9 Months Ended

Sep. 30, 2017

Stock Incentive Plan

Stock Incentive Plan

9. Stock Incentive Plan

The Company used the following weighted-average assumptions for options granted during the nine months ended September 30:


Nine months ended September 30,	2017		2016

Expected term (in years)	6.16		4.00
Expected volatility	50.72	%	61.71	%
Risk free rate	2.07	%	1.22	%
Expected dividends	—	%	—	%

At September 30, 2017, the total future stock compensation expense related to non-vested awards is expected to be approximately $9,086,000.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Public Offering of Common Stock	9 Months Ended
Public Offering of Common Stock	Sep. 30, 2017
Public Offering of Common Stock
Public Offering of Common Stock	10. Public Offering of Common Stock On October 7, 2016, AxoGen entered into an underwriting agreement with JMP Securities LLC, as representative of the several underwriters (collectively, the “Underwriters”), to issue and sell 2,333,334 shares of the Company’s common stock in an underwritten registered public offering (the “2016 Offering”) at an offering price of $7.50 per share. Pursuant to the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 350,000 shares of common stock, which the underwriters exercised in full on October 7, 2016. Five of the Company’s directors and officers purchased an aggregate of approximately 32,666 shares of common stock in the 2016 Offering and such purchases were made on the same terms and conditions as purchases by the public in the 2016 Offering. The 2016 Offering closed on October 13, 2016, and the Company received net proceeds of approximately $18.67 million from the sale of 2,683,334 shares of common stock, which includes the additional 350,000 shares of common stock, after deducting the underwriting discounts and commissions and estimated offering expenses.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies

Commitments and Contingencies

11. Commitments and Contingencies

Operating Leases

On March 16, 2016, AxoGen entered into the Fourth Amendment to Lease (“Fourth Amendment”) with SNH Medical Office Properties Trust (“SNH”). SNH is the landlord of AC’s currently leased 11,761 square foot corporate headquarters facility at 13631 Progress Boulevard, Suite 400, Alachua, Florida 32615 (the “Current Premises”) pursuant to that certain lease dated as of February 6, 2007, as amended (the “Existing SNH Lease”). The Fourth Amendment expands the Current Premises by 7,050 square feet (the “Expansion Premises”). The Fourth Amendment also provides that the Expiration Date (as defined in the Fourth Amendment) of the Existing SNH Lease will be extended to approximately five years from the Occupancy Date (as defined in the Fourth Amendment) which was June 2016. The original expiration date of the Current Premises remains unchanged; provided, however, that AC shall have the right to extend the Current Premises Term (as defined in the Fourth Amendment) for three additional periods (the “Current Premises Extended Term”), the first such Current Premises Extended Term to commence on November 1, 2018 and end on October 31, 2019, the second such Current Premises Extended Term to commence on November 1, 2019 and end on October 31, 2020, and the third such Current Premises Extended Term to commence on November 1, 2020 and end on the Expiration Date. AC also has the right to extend the term of the then current Leased Premises (as defined in the Fourth Amendment) for an additional period of five years commencing on the day immediately after the Expiration Date. AxoGen’s annual cost of such property ranges from approximately $248,000 to $332,000 per year.

In addition, AxoGen leases space and maintains records at certain other facilities, including the Company’s prior corporate headquarters at 1407 South Kings Highway, Texarkana, Texas 75501.

Estimated future minimum rental payments on the leases are as follows:


Year Ending December 31	Amount
2017 (9 months ended)	$	98,835
2018		437,900
2019		182,250
2020		165,116
2021		86,638
TOTAL	$	970,739

Total rent expense for the Company’s leased office and lab space for the nine months ended September 30, 2017 and 2016 was approximately $368,000 and $340,000, respectively.

Service Agreements

From 2009 to February 2016, AxoGen processed and packaged Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia (“LifeNet Health”). Business requirements of LifeNet Health led to their need for additional space and they notified AxoGen that AxoGen would need to transition out of the Virginia Beach facility on or before February 27, 2016. On August 6, 2015, AxoGen entered into a License and Services Agreement with Community Blood Center (d/b/a Community Tissue Services) (“CTS”), Dayton, Ohio, an FDA registered tissue establishment. Processing of the Avance® Nerve Graft pursuant to the CTS agreement began in February 2016. The CTS agreement is for a five-year term, subject to earlier termination by either party for cause, or after August 6, 2017 without cause, upon 18 months’ notice. Under the CTS agreement, AxoGen pays CTS a facility fee for clean room/manufacturing, storage and office space. CTS also provides services in support of AxoGen’s manufacturing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.

Certain executive officers of the Company are parties to employment contracts. Such contracts have severance payments for certain conditions including change of control.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Retirement Plan	9 Months Ended
Retirement Plan	Sep. 30, 2017
Retirement Plan
Retirement Plan	12. Retirement Plan AxoGen 401(k) Plan The Company adopted the AxoGen 401(k) plan (the “401(k) Plan”) in December 2015 with contributions starting in January 2016. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee’s annual salary and 1% of the next 2% of the employee’s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately. The Company contributed approximately $334,000 in matching funds during 2016. Employer contributions to the 401(k) Plan for the three months ending September 30, 2017 and 2016 were approximately $114,000 and $76,000, respectively, and for the nine months ending September 30, 2017 and 2016 were approximately $320,000 and $247,000, respectively.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2017
Summary of Significant Accounting Policies
Revenue Recognition	Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales, delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.
Cash and Cash Equivalents and Concentration	Cash and Cash Equivalents and Concentration For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.
Accounts Receivable and Concentration of Credit Risk	Accounts Receivable and Concentration of Credit Risk Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The allowance for doubtful accounts reserve balance was approximately $335,000 and $272,000 at September 30, 2017 and December 31, 2016, respectively. Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals and monitoring procedures.
Inventories	Inventories Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, Avive® Soft Tissue Membrane, AcroVal® Neurosensory and Motor Testing System, AxoTouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or market. We regularly review the inventory status to determine the expected reserve level required. The Company policy is to monitor the shelf life of its products and reserve amounts based on the expiration date of the finished goods inventory. We also reserve a portion of raw materials based on our historical experience of tissue that fails during the inspection and debridement stage due to medical history, serology compliance or poor quality.
Income Taxes	Income Taxes The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership. The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2014 through 2016; however, there currently are no examinations in process.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.
Share-Based Compensation	Share-Based Compensation The Company measures all employee stock-based compensation awards using a fair value method and records such expense in its consolidated financial statements. The estimated value of the portion of the award that is ultimately expected to vest, taking into consideration estimated forfeitures based on the Company’s historical forfeiture rate, is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the grant date fair value of stock option awards generally on the date of grant using the Black-Scholes option pricing model. With respect to performance stock units (“PSUs”), the number of shares that vest and are issued to the recipient is based upon the Company’s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company’s closing stock price on the grant date and its estimate of achieving such performance targets. See further discussion and disclosures in Note 9: “Stock Incentive Plan.”
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with USGAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.
Earnings (Loss) Per Share of Common Stock	Earnings (Loss) Per Share of Common Stock There were no dilutive instruments as of September 30, 2017 and 2016. The basic and diluted weighted average shares outstanding were 33,286,211 and 30,152,279 shares for the three months ended September 30, 2017 and 2016, respectively, and 33,146,546 and 30,075,715 shares for the nine months ended September 30, 2017 and 2016, respectively. Basic and diluted net loss per share of common stock for all periods presented is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding and common stock equivalents outstanding, when dilutive. Potentially dilutive common stock equivalents include shares of common stock which would potentially be issued pursuant to stock warrants and stock options. Common stock equivalents are not included in determining the fully diluted loss per share if their effect is antidilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (the “FASB”) issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the adoption date. During the quarter ended September 30, 2017, we completed the evaluation of the new standard and a related assessment and review of a representative sample of existing revenue contracts with our customers on our most significant revenue streams. Based upon this assessment, we do not believe there will be a material change to the timing of our revenue recognition. However, during the fourth quarter of 2017 we will continue our preparation for adopting the standard and periodically brief our Audit Committee on our progress. It is likely we will be required to provide additional disclosures in the notes to the consolidated financial statements upon adoption. We have not yet determined the effect of the ASU on our internal control over financial reporting or other changes in business practices and processes but will do so in the design and implementation phase to occur during the remainder of 2017. Additionally, we have not made a decision on which adoption method to utilize. Our evaluation of ASU 2014-09 is ongoing. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230). The ASU was issued intending to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this standard will have a material impact on our consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230), guidance that a statement of cash flows explains the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new guidance is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. We do not believe the adoption of this guidance will have a material impact on our Statement of Cash Flows. In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting.” ASU 2017-09 provides clarity on which changes to the terms or conditions of share-based payment awards require entities to apply the modification accounting provisions required in Topic 718. ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company does not expect that the adoption of ASU 2017-09 will have a material impact on the Company’s results of operations and financial condition. The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures

XML 29 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2017

Inventories

Schedule of inventories


	September 30,		December 31,
	2017		2016

Finished goods	$	5,157,260	$	4,132,036
Work in process		306,942		205,116
Raw materials		1,234,741		1,121,688
Inventories	$	6,698,943	$	5,458,840

XML 30 R20.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2017

Property and Equipment

Schedule of Property and equipment


	September 30,		December 31,
	2017		2016

Furniture and equipment	$	1,436,733	$	1,270,173
Leasehold improvements		711,319		447,650
Processing equipment		1,763,764		1,577,561
Less: accumulated depreciation and amortization		(2,147,976)		(1,801,137)
Property and equipment, net	$	1,763,840	$	1,494,247

XML 31 R21.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2017

Intangible Assets

Schedule of intangible assets


	September 30,		December 31,
	2017		2016

License agreements	$	1,003,512	$	984,342
Patents		461,712		308,212
Less: accumulated amortization		(513,751)		(463,575)
Intangible assets, net	$	951,473	$	828,979

XML 32 R22.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Accounts Payable and Accrued Expenses

Schedule of accounts payable and accrued expenses


	September 30,		December 31,
	2017		2016

Accounts payable	$	2,104,119	$	3,614,015
Accrued expenses		1,361,769		804,691
Accrued compensation		3,606,642		2,583,459
Accounts Payable and Accrued Expenses	$	7,072,530	$	7,002,165

XML 33 R23.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt (Tables)

9 Months Ended

Sep. 30, 2017

Term Loan Agreements and Long Term Debt

Schedule of Term Loan Agreements and Long Term Debt


	September 30,		December 31,
	2017		2016

Term Loan Agreement with MidCap Financial Trust (“MidCap”) for a total of $21,000,000, net of $663,946 of unamortized deferred financing fees at September 30, 2017, and $771,185 at December 31, 2016. Interest is payable monthly at 8.0% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 8.5% rate.	$	20,336,054	$	20,228,815

Revolving Loan Agreement with MidCap for up to $10,000,000 with borrowings based upon eligible accounts receivable and inventory. Interest is payable monthly at 4.5% per annum plus the greater of LIBOR or 0.5% which as of September 30, 2017 resulted in a 5.0% rate.		4,000,000		4,025,023

Equipment Lease Agreement with Cisco Capital for a total lease amount of $58,875 which has a 36 month term and requires no lease payments for the first three months of the lease and 33 equal payments of principal and interest until the end of the term. Interest on the lease is payable monthly at 3.5% per annum.		42,240		57,829
Total		24,378,294		24,311,667
Less current revolving loan		(4,000,000)		(4,025,023)
Less current maturities of long term debt		(21,596)		(20,899)
Long-term portion	$	20,356,698	$	20,265,745

Schedule of Maturities of Long Term Debt


Year Ending December 31	Amount
2017	$	5,310
2018		1,421,834
2019		8,415,096
2020		8,400,000
2021		2,800,000
		21,042,240
Less unamortized debt issuance costs		(663,946)
TOTAL	$	20,378,294

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan (Tables)

9 Months Ended

Sep. 30, 2017

Stock Incentive Plan

Schedule of weighted-average assumptions for options granted


Nine months ended September 30,	2017		2016

Expected term (in years)	6.16		4.00
Expected volatility	50.72	%	61.71	%
Risk free rate	2.07	%	1.22	%
Expected dividends	—	%	—	%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies

Schedule of estimated future minimum rental payments


Year Ending December 31	Amount
2017 (9 months ended)	$	98,835
2018		437,900
2019		182,250
2020		165,116
2021		86,638
TOTAL	$	970,739

XML 36 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Summary of Significant Accounting Policies
Reserve for accounts deemed uncollectible (as a percent)	100.00%		100.00%
Allowance for doubtful accounts reserve balance	$ 335,000		$ 335,000		$ 272,000
Earnings (Loss) Per Share of Common Stock
Dilutive instruments outstanding			0	0
Weighted Average Common Shares outstanding - basic and diluted	33,286,211	30,152,279	33,146,546	30,075,715

XML 37 R27.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Inventories
Finished goods	$ 5,157,260	$ 4,132,036
Work in process	306,942	205,116
Raw materials	1,234,741	1,121,688
Inventory, net	6,698,943	5,458,840
Inventory valuation reserves	$ 642,000	$ 960,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property and equipment
Less: accumulated depreciation and amortization	$ (2,147,976)	$ (1,801,137)
Property and equipment, net	1,763,840	1,494,247
Furniture and Equipment
Property and equipment
Property and equipment, Gross	1,436,733	1,270,173
Leasehold Improvements
Property and equipment
Property and equipment, Gross	711,319	447,650
Processing Equipment
Property and equipment
Property and equipment, Gross	$ 1,763,764	$ 1,577,561

XML 39 R29.htm IDEA: XBRL DOCUMENT

Intangible Assets - Components of Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Intangible assets consist of:
Less: accumulated amortization	$ (513,751)		$ (513,751)		$ (463,575)
Intangible assets, net	951,473		951,473		828,979
Patent costs			22,000
Amortization of Intangible Assets	19,000	$ 16,000	60,459	$ 48,050
Future amortization of license and patent agreements
Remainder of this year	19,000		19,000
Next five years	74,000		74,000
After year five	563,000		563,000
License Agreements
Intangible assets consist of:
Finite-lived intangible assets, gross	1,003,512		$ 1,003,512		984,342
License Agreements \| Minimum
Intangible assets consist of:
Amortization period of intangible assets			17 years
License Agreements \| Maximum
Intangible assets consist of:
Amortization period of intangible assets			20 years
Patents
Intangible assets consist of:
Finite-lived intangible assets, gross	$ 461,712		$ 461,712		$ 308,212
Amortization period of intangible assets			3 years
Non-amortizable pending costs			$ 461,712
Patents \| Maximum
Intangible assets consist of:
Amortization period of intangible assets			20 years

XML 40 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets - License Agreements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Intangible assets
Royalty fees included in sales and marketing expense			$ 860,000	$ 583,000
Sales and Marketing Expense
Intangible assets
Royalty fees included in sales and marketing expense	$ 319,000	$ 214,000
License Agreements
Intangible assets
License agreements extended period			60 days
Minimum royalty of agreements			$ 12,500
Milestone fee upon receiving a Phase II Small Business Innovation Research			15,000
Milestone fee upon FDA approval			2,000
Milestone fee upon first commercial use of certain licensed technology			25,000
Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products			$ 10,000
License Agreements \| Minimum
Intangible assets
Royalty fees range under the license agreements			1.00%
License Agreements \| Maximum
Intangible assets
Royalty fees range under the license agreements			3.00%
Royalty stack cap for royalties paid to more than one licensor for sales of the same product			3.75%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accounts Payable and Accrued Liabilities
Accounts payable	$ 2,104,119	$ 3,614,015
Accrued expenses	1,361,769	804,691
Accrued compensation	3,606,642	2,583,459
Accounts Payable and Accrued Expenses	$ 7,072,530	$ 7,002,165

XML 42 R32.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt - Schedule of Debt (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Note Payable
Long term debt	$ 24,378,294	$ 24,311,667
Less current revolving loan	(4,000,000)	(4,025,023)
Less current maturities of long term debt	(21,596)	(20,899)
Long-term portion	20,356,698	20,265,745
Equipment Lease Agreement
Note Payable
Long term debt	42,240	57,829
MidCap Loan \| Term Loan Agreement
Note Payable
Long term debt	20,336,054	20,228,815
MidCap Loan \| Revolver Credit facility
Note Payable
Long term debt	$ 4,000,000	$ 4,025,023

- Definition

The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 43 R33.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt - Schedule of Debt - Terms (Details) - USD ($)			9 Months Ended	12 Months Ended
	Oct. 25, 2016	Nov. 12, 2014	Sep. 30, 2017	Dec. 31, 2016	Nov. 13, 2014
Term Loan
Note Payable
Interest payable, percent			8.50%
Revolver Credit facility
Note Payable
Interest payable, percent			5.00%
Equipment Lease Agreement
Note Payable
Face amount			$ 58,875	$ 58,875
Interest payable, percent			3.50%	3.50%
Term of debt			36 months	36 months
No payments required, term			3 months	3 months
Interest and principal payments, term			33 months	33 months
Three Peaks Loan \| Term Loan Agreement
Note Payable
Face amount		$ 25,000,000
Interest payable, percent		9.00%
Interest rate spread		1.00%
Effective interest rate (as a percent)					10.00%
Term of debt		6 years
MidCap Loan \| Term Loan Agreement
Note Payable
Face amount	$ 21,000,000		$ 21,000,000	$ 21,000,000
Unamortized deferred financing fees			$ 663,946	$ 771,185
Interest payable, percent	8.00%		8.00%	8.00%
Interest rate spread	0.50%		0.50%	0.50%
Effective interest rate (as a percent)	0.25%		8.50%	8.50%
MidCap Loan \| Revolver Credit facility
Note Payable
Maximum line of credit amount	$ 10,000,000		$ 10,000,000	$ 10,000,000
Interest payable, percent	4.50%		4.50%	4.50%
Interest rate spread	0.50%		0.50%	0.50%
Effective interest rate (as a percent)			5.00%	5.00%

XML 44 R34.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revenue Interest Agreement (Details) - USD ($) $ in Millions	Nov. 12, 2014	Sep. 30, 2017
Term Loan
Debt Instrument [Line Items]
Interest payable, percent		8.50%
Three Peaks Loan \| Revenue Interest Purchase Agreement
Debt Instrument [Line Items]
Royalty percentage on net revenue	3.75%
Maximum revenue subject to royalties payable calculation	$ 30
Aggregate revenues subject to royalties payable, term	12 months

XML 45 R35.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revolving Loan (Details)				9 Months Ended	12 Months Ended
	Oct. 26, 2016	Oct. 25, 2016 USD ($) item	Nov. 12, 2014 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2016 USD ($)	Nov. 13, 2014
Debt Instrument [Line Items]
Exit fee percent		5.00%
Debt issuance costs				$ 29,472
Three Peaks Loan
Debt Instrument [Line Items]
Payments of Debt Extinguishment Costs		$ 2,300,000
MidCap Loan
Debt Instrument [Line Items]
Proceeds from issuance of debt		25,000,000
Debt issuance costs		800,000
Term Loan Agreement \| Three Peaks Loan
Debt Instrument [Line Items]
Face amount			$ 25,000,000
Interest payable, percent			9.00%
Interest rate spread			1.00%
Effective interest rate (as a percent)						10.00%
Term Loan Agreement \| MidCap Loan
Debt Instrument [Line Items]
Face amount		$ 21,000,000		$ 21,000,000	$ 21,000,000
Number of months requiring principal and interest payments \| item		30
Interest payable, percent		8.00%		8.00%	8.00%
Interest rate spread		0.50%		0.50%	0.50%
Effective interest rate (as a percent)		0.25%		8.50%	8.50%
Revolver Credit facility
Debt Instrument [Line Items]
Interest payable, percent				5.00%
Revolver Credit facility \| MidCap Loan
Debt Instrument [Line Items]
Interest payable, percent		4.50%		4.50%	4.50%
Interest rate spread		0.50%		0.50%	0.50%
Effective interest rate (as a percent)				5.00%	5.00%
Prepayment fee percent, year one	3.00%
Prepayment fee percent, year two	2.00%
Prepayment fee percent, thereafter	1.00%
Maximum line of credit amount		$ 10,000,000		$ 10,000,000	$ 10,000,000
Collateral management fee, percent		0.50%
Unused line fee, percent		0.50%
Percent of Borrowing Base which accrues interest		30.00%
Revolver Credit facility \| MidCap Loan \| Maximum
Debt Instrument [Line Items]
Maximum line of credit amount		$ 15,000,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Interest Expense	$ 577,941	$ 1,089,134	$ 1,639,874	$ 3,255,574	$ 5,386,000	$ 3,989,000
Repayments of Long-term Debt			15,589
Amortization of Financing Costs and Discounts	46,110	$ 31,748	136,711	$ 95,254
Write Off Of Deferred Financing Costs					750,000
Term Loan
Debt Instrument [Line Items]
Amount outstanding	$ 21,000,000		$ 21,000,000
Interest payable, percent	8.50%		8.50%
Revolver Credit facility
Debt Instrument [Line Items]
Amount outstanding	$ 4,000,000		$ 4,000,000
Interest payable, percent	5.00%		5.00%
Borrowing amount available	$ 6,879,000		$ 6,879,000
Three Peaks Loan
Debt Instrument [Line Items]
Interest Expense					1,700,000
Repayments of Long-term Debt					2,447,000
Amortization of Financing Costs and Discounts					$ 747,000

XML 47 R37.htm IDEA: XBRL DOCUMENT

Term Loan Agreements and Long Term Debt - Annual Maturities (Details)	Sep. 30, 2017 USD ($)
Minimum annual payment amounts
2017	$ 5,310
2018	1,421,834
2019	8,415,096
2020	8,400,000
2021	2,800,000
Total, before debt issuance costs	21,042,240
Less unamortized debt issuance costs	(663,946)
Total	$ 20,378,294

XML 48 R38.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
Stock Incentive Plan - Narrative (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	May 24, 2017
Stock Option disclosures
Options, Granted (in shares)			635,525
Weighted average grant-date fair value of options granted (in dollars per share)			$ 6.77	$ 3.00
Stock Options
Stock Option disclosures
Total future stock compensation expense related to nonvested awards	$ 9,086,000		$ 9,086,000
AxoGen 2010 Stock Incentive Plan [Member]
Stock Option disclosures
Shares authorized for issuance	5,500,000		5,500,000		7,700,000
AxoGen 2010 Stock Incentive Plan [Member] \| Employee Consultants and Directors Stock Options [Member] \| Minimum
Stock Option disclosures
Vesting period			7 years
AxoGen 2010 Stock Incentive Plan [Member] \| Employee Consultants and Directors Stock Options [Member] \| Maximum
Stock Option disclosures
Vesting period			10 years
AxoGen 2010 Stock Incentive Plan [Member] \| Stock Options
Stock Option disclosures
Vesting period			4 years
Share-based compensation expense	$ 919,026	$ 293,575	$ 2,491,992	$ 1,046,364
AxoGen 2010 Stock Incentive Plan [Member] \| Stock Options \| One Year After Grant Date
Stock Option disclosures
Vesting percentage			25.00%
AxoGen 2010 Stock Incentive Plan [Member] \| Stock Options \| Every Six Months
Stock Option disclosures
Vesting percentage			12.50%
Vesting period			3 years
AxoGen 2010 Stock Incentive Plan [Member] \| Directors and Officers Stock Options [Member]
Stock Option disclosures
Vesting percentage			25.00%
Vesting period			1 year
AxoGen 2010 Stock Incentive Plan [Member] \| Directors and Officers Stock Options [Member] \| Minimum
Stock Option disclosures
Vesting period			3 years
AxoGen 2010 Stock Incentive Plan [Member] \| Directors and Officers Stock Options [Member] \| Maximum
Stock Option disclosures
Vesting period			4 years
AxoGen 2017 Employee Stock Purchase Plan [Member]
Stock Option disclosures
Shares authorized for issuance					600,000

XML 49 R39.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Summary of Weighted-Average Assumptions Used for Options Granted (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Weighted-average assumptions
Expected term	6 years 1 month 28 days	4 years
Expected volatility (as a percent)	50.72%	61.71%
Risk free rate (as a percent)	2.07%	1.22%

XML 50 R40.htm IDEA: XBRL DOCUMENT

Public Offering of Common Stock (Details) $ / shares in Units, $ in Thousands	Oct. 13, 2016 USD ($) shares	Oct. 07, 2016 item $ / shares shares	Sep. 30, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares
Shares of common stock sold			33,393,804	33,008,865
Par value of common stock \| $ / shares			$ 0.01	$ 0.01
October 2016 Offering
Shares of common stock sold		2,333,334
Public offering price (in dollars per share) \| $ / shares		$ 7.50
Number of days to underwriter to sell additional common shares		30 days
October 2016 Offering inclusive of over-allotment option
Shares of common stock sold	2,683,334
Proceeds from Issuance of Common Stock \| $	$ 18,670
Underwriting Agreement
Shares of common stock sold	350,000	350,000
Directors and officers \| October 2016 Offering
Shares of common stock sold		32,666
Number of directors and officers who purchased common stock \| item		5

XML 51 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Narrative (Details)	Jan. 23, 2017 USD ($) ft²	Oct. 25, 2016 USD ($) ft²	Mar. 16, 2016 USD ($) ft²	Oct. 25, 2013 USD ($) ft²
SNH \| 13631 Progress Boulevard, Suite 400, Alachua, Florida 32615
Commitments and Contingencies
Additional leased office space in square feet \| ft²			7,050
Leased office space in square feet \| ft²			11,761
Term of agreement			5 years
Additional term of agreement, if extended			3 years
Additional extension term after expiration date			5 years
SNH \| 13709 Progress Boulevard, Alachua, Florida 32615
Commitments and Contingencies
Leased office space in square feet \| ft²	1,431
Term of agreement	5 years
SNH \| Minimum \| 13631 Progress Boulevard, Suite 400, Alachua, Florida 32615
Commitments and Contingencies
Annual lease expense \| $			$ 248,000
SNH \| Minimum \| 13709 Progress Boulevard, Alachua, Florida 32615
Commitments and Contingencies
Annual lease expense \| $	$ 25,800
SNH \| Maximum \| 13631 Progress Boulevard, Suite 400, Alachua, Florida 32615
Commitments and Contingencies
Annual lease expense \| $			$ 332,000
SNH \| Maximum \| 13709 Progress Boulevard, Alachua, Florida 32615
Commitments and Contingencies
Annual lease expense \| $	$ 29,000
Ja-Cole
Commitments and Contingencies
Additional leased office space in square feet \| ft²		2,500		2,100
Leased office space in square feet \| ft²		10,000		5,400
Term of agreement				3 years
Annual lease expense \| $		$ 88,000		$ 43,200

XML 52 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Estimated Future Minimum Rental Payments (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Estimated future minimum rental payments on the leases
2017	$ 98,835
2018	437,900
2019	182,250
2020	165,116
2021	86,638
TOTAL	970,739
Total rent expense	$ 368,000	$ 340,000

XML 53 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Service Agreements (Details) - USD ($)		9 Months Ended
	Aug. 06, 2015	Sep. 30, 2017	Dec. 31, 2011
Tissue Processing Agreement [Member]
Service Agreements
Term of agreement	5 years
Commitment extension period		18 months
Master Services Agreement For Clinical Research and Related Services [Member]
Service Agreements
Company is required to pay execution of the agreement			$ 151,318

XML 54 R44.htm IDEA: XBRL DOCUMENT

Retirement Plan (Details)	3 Months Ended		9 Months Ended		12 Months Ended
Retirement Plan (Details)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) item	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Defined Benefit Plan
Age limit for eligibility to participate in the plan \| item			18
AxoGen 401K Plan
Defined Benefit Plan
Employer contributions \| $	$ 114,000	$ 76,000	$ 320,000	$ 247,000	$ 334,000
Axogen 401K Plan, employee's contribution of first 3% of annual salary
Defined Benefit Plan
Matching contributions			3.00%
Employee contribution matched, percent			3.00%
Axogen 401K Plan, employee's contribution of next 2% of annual salary
Defined Benefit Plan
Matching contributions			1.00%
Employee contribution matched, percent			2.00%

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 101 201 1 false 35 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.axogeninc.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 10201 - Disclosure - Organization and Business Sheet http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10401 - Disclosure - Inventories Sheet http://www.axogeninc.com/role/DisclosureInventories Inventories Notes 9 false false R10.htm 10501 - Disclosure - Property and Equipment Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 10601 - Disclosure - Intangible Assets Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssets Intangible Assets Notes 11 false false R12.htm 10701 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 12 false false R13.htm 10801 - Disclosure - Term Loan Agreements and Long Term Debt Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt Term Loan Agreements and Long Term Debt Notes 13 false false R14.htm 10901 - Disclosure - Stock Incentive Plan Sheet http://www.axogeninc.com/role/DisclosureStockIncentivePlan Stock Incentive Plan Notes 14 false false R15.htm 11001 - Disclosure - Public Offering of Common Stock Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock Public Offering of Common Stock Notes 15 false false R16.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 11201 - Disclosure - Retirement Plan Sheet http://www.axogeninc.com/role/DisclosureRetirementPlan Retirement Plan Notes 17 false false R18.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30403 - Disclosure - Inventories (Tables) Sheet http://www.axogeninc.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.axogeninc.com/role/DisclosureInventories 19 false false R20.htm 30503 - Disclosure - Property and Equipment (Tables) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.axogeninc.com/role/DisclosurePropertyAndEquipment 20 false false R21.htm 30603 - Disclosure - Intangible Assets (Tables) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.axogeninc.com/role/DisclosureIntangibleAssets 21 false false R22.htm 30703 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses 22 false false R23.htm 30803 - Disclosure - Term Loan Agreements and Long Term Debt (Tables) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTables Term Loan Agreements and Long Term Debt (Tables) Tables http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebt 23 false false R24.htm 30903 - Disclosure - Stock Incentive Plan (Tables) Sheet http://www.axogeninc.com/role/DisclosureStockIncentivePlanTables Stock Incentive Plan (Tables) Tables http://www.axogeninc.com/role/DisclosureStockIncentivePlan 24 false false R25.htm 31103 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 40301 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 40401 - Disclosure - Inventories (Details) Sheet http://www.axogeninc.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.axogeninc.com/role/DisclosureInventoriesTables 27 false false R28.htm 40501 - Disclosure - Property and Equipment (Details) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables 28 false false R29.htm 40601 - Disclosure - Intangible Assets - Components of Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails Intangible Assets - Components of Intangible Assets (Details) Details 29 false false R30.htm 40602 - Disclosure - Intangible Assets - License Agreements (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails Intangible Assets - License Agreements (Details) Details 30 false false R31.htm 40701 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) Details http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables 31 false false R32.htm 40801 - Disclosure - Term Loan Agreements and Long Term Debt - Schedule of Debt (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtDetails Term Loan Agreements and Long Term Debt - Schedule of Debt (Details) Details 32 false false R33.htm 40802 - Disclosure - Term Loan Agreements and Long Term Debt - Schedule of Debt - Terms (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtScheduleOfDebtTermsDetails Term Loan Agreements and Long Term Debt - Schedule of Debt - Terms (Details) Details 33 false false R34.htm 40803 - Disclosure - Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revenue Interest Agreement (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTermLoanAgreementAndRevenueInterestAgreementDetails Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revenue Interest Agreement (Details) Details 34 false false R35.htm 40804 - Disclosure - Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revolving Loan (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtTermLoanAgreementAndRevolvingLoanDetails Term Loan Agreements and Long Term Debt - Term Loan Agreement and Revolving Loan (Details) Details 35 false false R36.htm 40805 - Disclosure - Term Loan Agreements and Long Term Debt - Additional Information (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtAdditionalInformationDetails Term Loan Agreements and Long Term Debt - Additional Information (Details) Details 36 false false R37.htm 40806 - Disclosure - Term Loan Agreements and Long Term Debt - Annual Maturities (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementsAndLongTermDebtAnnualMaturitiesDetails Term Loan Agreements and Long Term Debt - Annual Maturities (Details) Details 37 false false R38.htm 40901 - Disclosure - Stock Incentive Plan - Narrative (Details) Sheet http://www.axogeninc.com/role/DisclosureStockIncentivePlanNarrativeDetails Stock Incentive Plan - Narrative (Details) Details 38 false false R39.htm 40902 - Disclosure - Stock Incentive Plan - Summary of Weighted-Average Assumptions Used for Options Granted (Details) Sheet http://www.axogeninc.com/role/DisclosureStockIncentivePlanSummaryOfWeightedAverageAssumptionsUsedForOptionsGrantedDetails Stock Incentive Plan - Summary of Weighted-Average Assumptions Used for Options Granted (Details) Details 39 false false R40.htm 41001 - Disclosure - Public Offering of Common Stock (Details) Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails Public Offering of Common Stock (Details) Details http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock 40 false false R41.htm 41101 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 41 false false R42.htm 41102 - Disclosure - Commitments and Contingencies - Estimated Future Minimum Rental Payments (Details) Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesEstimatedFutureMinimumRentalPaymentsDetails Commitments and Contingencies - Estimated Future Minimum Rental Payments (Details) Details 42 false false R43.htm 41103 - Disclosure - Commitments and Contingencies - Service Agreements (Details) Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesServiceAgreementsDetails Commitments and Contingencies - Service Agreements (Details) Details 43 false false R44.htm 41201 - Disclosure - Retirement Plan (Details) Sheet http://www.axogeninc.com/role/DisclosureRetirementPlanDetails Retirement Plan (Details) Details http://www.axogeninc.com/role/DisclosureRetirementPlan 44 false false All Reports Book All Reports axgn-20170930.xml axgn-20170930.xsd axgn-20170930_cal.xml axgn-20170930_def.xml axgn-20170930_lab.xml axgn-20170930_pre.xml http://fasb.org/us-gaap/2016-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 61 0001558370-17-007934-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-17-007934-xbrl.zip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end